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THE EDITOR…
It seems an eternity since I wrote my last editorial, peak-pandemic. I think a COVID-19 month is 
equal to a non-COVID year, and I can barely remember life BC (‘before COVID’). Watching TV 
cricket highlights on ‘Ben Stokes day’ and the amazing Bowie set at Glastonbury, I find it hard to 
imagine being anywhere crowded ever again. Sadly, but inevitably, SfE BES 2020 will be virtual this 
year (you will find the programme on page 17), and we will have to wait a little longer before we can 
meet up to share our stories.
In this issue, we share some experiences of  how endocrinologists have adapted during the pandemic. 
Risheka Walls and colleagues discuss running virtual endocrinology masterclasses (page 6), whilst 
Caroline Gorvin and Mark Turner demonstrate how to run a lab from our living rooms (page 18). 
On page 26, Steve Ball reflects on how rapidly things changed in March, and describes principles to 
consider as we rebuild our endocrinology services. You will find the Society for Endocrinology’s work 
looking at the future of  endocrinology on page 22. 
Then, reminding us there is life apart from coronavirus, we have some articles on the science of  
cancer, including those of  the breast (page 7) and prostate (page 9) and neuroendocrine tumours 
(page 10). Caroline Maslin (page 14) writes about how it feels to be a patient living with cancer, how it 
affects lives in ways that are not immediately apparent. She emphasises the importance of  discussing 
the consequences of  treatments before irreversible decisions are made.
As our children go back to school, those not in key services go back to work, and COVID-19 cases 
rise again, I wonder where we will be in another 3 months. I hope we will not see a full blown second 
wave, although some will already have experienced local lockdowns. I hope you all had time away 
from work over the summer to pause, refresh and relax. Keep safe as we go into autumn and then 
winter. Go well, team endocrinology.
HELEN SIMPSON
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ENDOCRINE SERVICES DURING 
THE COVID-19 RESET 
The Association of  British Clinical Diabetologists, in close 
collaboration with your Society and the Royal College of  
Physicians (London), has issued new guidance on which 
core diabetes and endocrine clinical services the NHS can 
provide in the face of  major disruption and reduced capacity 
for clinical teams. It is hoped that it will provide a useful 
framework for clinical team leaders and managers during any 







In reaction to the global coronavirus 
pandemic, the Bioscientifica Trust has 
launched a new COVID-19 response fund, 
providing up to €5,000/£5,000. This fund is 
aimed at early career scientists or clinicians 
to help address the disruption caused by the 
virus. The new fund can be utilised flexibly, 
for example to cover short term salary 
support, travel, equipment, consumable  
costs etc. 
Find out more and apply at  
www.bioscientificatrust.org.
WITH REGRET
We are sorry to announce the death of  former Member and Society for 
Endocrinology Medallist, Professor Gerald Lincoln. A full obituary will appear in a 
future issue of  The Endocrinologist. 
NEW HUB FOR CAREER 
ADVICE & SUPPORT 
Check out our new collection of  resources, providing tips 
and advice to help advance your career. You can find 
anything from CV help to alternative endocrine careers, for 
any career stage. Share your own with the community by 




TO OUR 2020 EARLY 
CAREER PRIZE 
LECTURERS
Steve Millership from Imperial College London 
is our winning clinical/translational prize lecturer 
and was selected for his abstract, ‘Tracking of 
imprinted gene hypervariability and diet-induced 
deregulation in pancreatic beta cells.’
Kate Lines from the University of Oxford is our 
winning science lecturer and was selected for her 
abstract, ‘Targeting epigenetic mechanisms as a 
novel treatment for MEN1-associated tumours.’
Both winners will present their lectures at  
SfE BES Online.
JOHN BEVAN’S CHARITY 
FUNDRAISER
We congratulate and applaud 
retired endocrinologist and 
senior Society member, John 
Bevan, who has raised almost 
£15,000 for charity during 
the COVID-19 lockdown by 
walking one million steps. As a 
stroke survivor, he decided to 
help some neglected charities 
during the pandemic by being 
sponsored to walk a million steps 
in his garden – equivalent to 417 
miles. At a speed of  just under 
3mph, the walk took 145 hours and was completed on 1 






We have started a project to review our 
governance structures and processes. This is 
to ensure that the Society is operating in line 
with current best practice and is therefore 
able to fulfil its mission in the most effective 
way. It is best practice to do a governance 
review every 5 years. The work will be led 
by members and Professor Karen Chapman 
has been appointed as Chair of  the working 
group.
If  you have any particular areas that you 
feel should be addressed please let us 
know at members@endocrinology.
org and we will put you directly in touch 
with the working group. All members will 
be consulted on the recommendations that 
come out of  the governance review before 




We are delighted to welcome Aled Rees  
(Cardiff) and Maralyn Druce (London) as the  
new Senior Editors of  the Society’s journal  
Clinical Endocrinology. 
You can find the journal online at www.
onlinelibrary.wiley.com/journal/13652265.Aled Rees Maralyn Druce
HELP IMPROVE SCIENCE  
REPORTING IN THE MEDIA
Become a Society Media Ambassador and share your  
expertise to improve accuracy in media coverage of  endocrine 
related topics. Find out more www.endocrinology.org/ 
outreach/public-engagement.
PKA functions in metabolism and resistance to obesity
In follow up to Constantine Stratakis’ 2019 SfE BES Dale Medal Lecture, 
this article provides a comprehensive review discussing the role of  the cAMP-
dependent protein kinase (PKA) in co-ordinating metabolic responses. 
Presenting evidence from studies of  human epidemiology, endocrine disease and 
obesity, combined with rodent knockout models, London et al. systematically 
evaluate the evidence for the roles of  this ubiquitous signalling molecule and the 
upstream/downstream Gsα signalling pathway components. They cover aspects 
including tissue-specific functionalities of  PKA/the PKA pathway via knockout 
animals, through roles of  PKA in hypothalamic and central energy sensing, and 
energy sensing/storage and expenditure and insulin secretion. 
Read the full article in Journal of  Endocrinology 246 R51–R64
Anti-inflammatory effects of androgens in human vagina
Genitourinary syndrome of  menopause (GSM) affects approximately 50% of  
postmenopausal women. It is characterised by vulvovaginal atrophy and lower 
urinary tract symptoms which adversely affect sexual health and general well-
being. These symptoms are primarily a consequence of  reduced oestrogens at 
menopause. However, androgens, which also decline with age, are increasingly 
recognised as important regulators of  genitourinary tissue function. Importantly, 
androgen treatment may have beneficial effects in the vagina by modulating 
inflammatory responses.
Maseroli and colleagues investigated whether androgens could modulate the 
inflammatory response in the vagina by assessing human vaginal tissues and 
human distal vagina smooth muscle cells isolated from postmenopausal women. 
They investigated the expression of  sex steroid receptors and assessed the 
effect of  the selective androgen receptor agonist dihydrotestosterone (DHT) 
on inflammatory responses. The authors found that androgen receptor was 
expressed in vaginal smooth muscle cells and that DHT reduced basal secretion 
of  pro-inflammatory cytokines, chemokines and growth factors. DHT also 
decreased secretion of  cytokines induced by the pro-inflammatory stimulus 
lipopolysaccharide.
These results suggests that androgens have an anti-inflammatory effect on 
vaginal smooth muscle cells which may have therapeutic benefit in the treatment 
of  GSM.
Read the full article in Journal of  Molecular Endocrinology  
doi:10.1530/JME-20-0147 
JOURNAL OF MOLECULAR ENDOCRINOLOGY
High fat diet in pregnancy and mammary cancer recurrence in 
offspring
Maternal obesity can affect the health of  offspring and is associated with 
increased risk of  metabolic disorders. Because it is linked to high birth weight, 
it may also increase a daughter’s breast cancer risk and increase breast cancer 
mortality.
Zhang and colleagues used rodent models of  premenopausal breast cancer to 
investigate whether maternal obesity could affect a female offspring’s response to 
tamoxifen treatment and risk of  recurrence after tamoxifen administration. They 
found that maternal exposure to an obesogenic high fat diet during pregnancy 
could programme an offspring’s mammary glands to develop carcinogen-
initiated mammary tumours at a younger age. Maternal high fat diet during 
pregnancy was also associated with an increase in allografted mammary tumour 
burden compared with control diet, and an increased risk of  mammary cancer 
recurrence after tamoxifen administration. These responses were associated with 
an impaired tumour immune response characterised by altered T cell function.
These findings suggest that maternal high fat diet in pregnancy increases 
offspring susceptibility to mammary tumour growth, cancer recurrence and 
suppression of  tumour immune responses.
Read the full article in Endocrine-Related Cancer 27 469–482
ENDOCRINE-RELATED CANCER
ENDOCRINE HIGHLIGHTS
A summary of papers from around the endocrine community that have got you talking.
©Shutterstock
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HOT TOPICS
Mammographic screening from age 40 and breast cancer mortality 
Breast cancer screening programmes in the UK offer mammograms every 3 years to 
women aged 50–70. However, the cost:benefit ratio regarding the public health benefits 
versus technical issues associated with screening women from the age of  40 remains 
under debate.
This randomised, controlled trial conducted by Duffy et al. investigated the effects 
of  earlier mammogram screening for prevention of  breast cancer mortality. A total 
of  160,921 participants were recruited into 23 breast screening units. They were 
stratified by general practice into yearly mammogram screening up to 48 years of  age 
(intervention), or to standard care of  no screening until invitation at ~50 years of  age 
into the national screening programme (control). Participants were followed up for a 
median of  22.8 years.
A significant (~25%) reduction was seen in breast cancer mortality in the first 10 years 
of  follow up in the intervention group. However, there was no significant reduction in 
the intervention group with follow up after 10 years.
Read the full article in Lancet Oncology doi:10.1016/S1470-2045(20)30398-3
Society members have free access to the current  
content of Journal of Endocrinology, Journal of Molecular 
Endocrinology, Endocrine-Related Cancer and Clinical 
Endocrinology via the members’ area on the Society home 
page, www.endocrinology.org. Endocrine Connections and 
Endocrinology, Diabetes & Metabolism Case Reports, the 
Society-endorsed case reports publication, are open  
access and free to all.




Role of MICOS assembly in crista formation
The ability of  mitochondria to complete critical functions such as ATP generation and lipid metabolism 
is a product of  their iconic structure. It has also long been understood that aberrances in the folds of  
mitochondrial cristae are associated with numerous, severe, life-limiting human conditions. Despite their 
clear importance to human health, the molecular processes dictating their formation and also wider 
mitochondrial architecture are poorly understood. 
Stephan et al. recently increased our knowledge in this area by using CRISPR-Cas9 to knock out individual 
genes of  the human MICOS (mitochondrial contact site and cristae organising system) along with super-
resolution microscopy techniques to capture images of  the structure of  single mitochondria. They discovered 
that individual proteins within the MICOS are associated with specific aspects of  crista formation, with each 
one playing a role in tightly co-ordinated organisation. Interestingly, they also found that crista precursors are 
first formed prior to remodelling by the MICOS complex. 
As a result of  these experiments, they propose a new model for mitochondrial crista formation in higher 
eukaryotes distinct from that in lower eukaryotes. This advancement in knowledge moves us towards a better 
grasp of  the genetic and physical interactions that give rise to the unique energy-generating organelles inside 
our cells. 
Read the full article in EMBO Journal doi:10.15252/embj.2019104105
Hot Topics is written by Craig Doig, Douglas Gibson, Louise Hunter, Kim Jonas and Helen Simpson.
Short term SGLT2 inhibitor use improves skeletal muscle insulin 
sensitivity
Sodium–glucose co-transporter 2 (SGLT2) inhibitors exert their actions within 
the kidneys, serving an important glucose-lowering effect in the treatment of  
diabetes mellitus. However, it is unclear if  SGLT2 inhibitors can impact glucose 
sensitivity of  skeletal muscle during short term administration. 
Goto et al. examined 20 individuals experiencing T2DM and their response 
to a single week’s treatment with empagliflozin, a common SGLT2 inhibitor. 
The study measured relevant metabolic outcomes following SGLT2 inhibition, 
including low and high density lipoproteins and urinary glucose levels. In 
addition, the work measured skeletal muscle mass, through body composition 
using bioimpedance. This experiment revealed that 1 week’s administration 
of  empagliflozin significantly decreases body mass index as well as overall fat 
and skeletal muscle mass. Plasma glucose also demonstrated reduced levels, 
indicating a decline in insulin concentrations. 
The authors suggest that SGLT2 inhibitor-associated elevation of  glucose 
metabolism may occur through skeletal muscle mitochondrial metabolism 
and intramyocellular lipid mobilisation. Whilst much work remains to be done 
to fully appreciate the mechanism and implications of  SGLT2 inhibition for 
specific tissues, these experiments demonstrate that short term exposure to 
SGLT2 can evoke substantial shifts in body composition, plasma glucose and 
skeletal muscle.
Read the full article in Endocrine Connections 9 599–606
ENDOCRINE CONNECTIONS
CLINICAL ENDOCRINOLOGY
When primary hyperparathyroidism comes as good news 
Clinicians in Varese report a case of  a rarely observed consequence of  primary 
hyperparathyroidism – multiple brown tumours initially misdiagnosed as 
malignant osteosarcoma. Brown tumours can occur when osteoclast activity is 
especially high, resulting in haemorrhage and fibrosis within the bone marrow. 
The brown colour is imparted by a build-up of  haemosiderin.
For the 70-year-old patient reported in this case study, chest X-ray incidentally 
detected an 8cm axillary mass, showing local invasion on CT, concurrent 
with hypercalcaemia. Giant cell-rich osteosarcoma was high on the list of  
initial diagnoses. Lesions were detected elsewhere in the skeleton. However, 
immunohistochemistry findings were not in keeping with malignancy and, 
instead, demonstrated haemorrhage and haemosiderin deposition. Parathyroid 
hormone levels, which were then measured, were elevated. Subsequent 
investigations led to the discovery of  a large right-sided parathyroid adenoma. 
The patient was therefore treated with parathyroid surgery plus denosumab to 
improve bone density.
The authors reflect on the unusual nature of  this case, in an era when primary 
hyperparathyroidism is frequently detected early, before complications have 
developed. They also comment on the value of  the histopathology input, which 
led to the true diagnosis. This carried a profoundly different prognosis to the 
more sinister conditions initially suspected.
Read the full article in Endocrinology, Diabetes & Metabolism Case Reports  
doi:10.1530/EDM-20-0046
Self-reported adverse lifestyle factors in men with sub-fertility
Sperm counts are falling, fertility is declining, and there are no pharmacological 
interventions to improve sperm quality. Add to that COVID-19 and the human 
race is clearly doomed. 
Jayasena et al. describe lifestyle factors (LSFs) in a cohort of  1,149 male partners 
of  couples under investigation for sub-fertility. Factors such as smoking, 
recreational drug use, alcohol, caffeine intake and obesity are known to 
affect fertility. In this study, 70% of  men reported one or more LSFs affecting 
fertility, and 29% reported two or more. Education also correlated with sperm 
count, with those men achieving undergraduate education or higher having 
a higher sperm count. When asked, 79% of  the men expressed a desire for 
more information about how to improve fertility, such as leaflets, videos, online 
educational resources and more education at schools. 
There is evidence that reducing some of  these factors improves sperm count, 
but no prospective studies currently show improvements in fertility. These data 
suggest, however, that optimising health by providing early health education and 
educational resources when considering fertility may be an effective strategy. 
Hopefully, there will be follow-up data to show efficacy of  such an approach in 
the future.
Read the full article in Clinical Endocrinology 93 312−321
ENDOCRINOLOGY, DIABETES & METABOLISM CASE REPORTS
HT
©Shutterstock
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Administration of systemic corticosteroids 
and mortality from COVID-19
This month JAMA published several studies looking 
at the efficacy of  steroids in severe COVID-19. 
The REAMP-CAP paper suggested some benefit 
for hydrocortisone in patients, data analysis used 
complex Bayesian statistics, which are beyond the 
capability of  this author to explain. The trial was 
stopped early and no treatment strategy met pre-
specified criteria for statistical superiority, precluding 
definitive conclusions. However, the meta-analysis 
from the WHO Rapid Evidence Appraisal for 
COVID-19 Therapies (REACT) Working Group 
showed benefits for corticosteroids more generally. 
This meta-analysis was of  7 randomised trials, 
across 12 different countries including 1,703 patients 
with severe SARS-CoV-2 infection in an intensive 
care setting, of  whom 647 died. Patients received 
intravenous dexamethasone, hydrocortisone or 
(in a small number of  cases) methylprednisolone. 
There were 222 deaths among the 678 patients 
randomised to corticosteroids and 425 deaths 
among the 1,025 patients randomised to usual care 
or placebo (summary odds ratio, 0.66 [95% CI, 
0.53-0.82]; P<0.001 based on a fixed-effect meta-
analysis). This is exciting news in the management 
of  severe COVID-19. From an endocrine 
perspective, it does not affect the usual management 
of  patients with adrenal insufficiency (AI) and the 
NHS England central pharmacy team are aware 
that hydrocortisone is a critical drug for AI patients, 
so are monitoring stocks on a weekly basis, which 
should provide reassurance for our patients.
Read the full articles in JAMA doi:10.1001/
jama.2020.17022 and doi:10.1001/jama.2020.17023 
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MAKE IT ENGAGING
Effectively delivering an online conference with audience participation is an 
evolving process. All the presenters built in interactive questions, put to the 
audience via Mentimeter (www.menti.com). The audience could test their 
own knowledge and views against that of  fellow endocrinologists through 
summary graphs (Figure 1). The presenter was also able to ‘read the room’, 
gauge the audience’s learning needs and adapt subsequent discussions.
BE DYNAMIC AND ADAPTABLE
Feedback is vital for improvement, and yet conference feedback can only 
be actioned 12 months post-event. Through our short but regular sessions, 
feedback from one session was actioned for the following fortnightly 
session. For instance, the first session saw a demand for expert teaching on 
osteoporosis. We therefore adapted the following session by opening with 
30 minutes of  osteoporosis teaching from a metabolic bone consultant, 
and ‘Alex’s osteoblast’ has become a regular feature. Using the chat box 
function on Zoom, we were able to take both real time questions during the 
presentation and questions at the end.
INCLUSION AND EMPOWERMENT
Our Zoom platform saw the majority of  questions asked by trainees, 
which contrasts with ‘live’ large conferences. Each talk generated seven to 
ten questions from the audience, with 70% from trainees. The freedom to 
type questions, combined with an appreciation of  the level of  knowledge 
amongst the audience through Mentimeter, empowers those less vocal to 
speak up.
WHAT’S IN IT FOR ME?
Learning is great, but learning with Continuing Professional Development 
(CPD) is even better. We proactively approached the Royal College of  
Physicians who approved each session for two CPD points. Points were 
obtained by photographing a QR code displayed intermittently throughout 
the session. This linked directly to a feedback page and resulted in 90% of  
candidates completing feedback on the day. As conference organisers, we 
stand to gain too, as such instantaneous feedback helps us plan and adapt 
the next fortnightly session.
Physical conferences have provided opportunities to visit new places, 
collaborate over coffee and mingle with friends and experts. Yet, we have 
all missed conferences through rota clashes, personal commitments or 
a tight budget. Once missed, the next opportunity is often 12 months 
away. Through our Zoom bite-sized Masterclass, we were able to deliver 
Conferences see thousands of  like-minded people coming together to 
learn and network, and generate over £19 billion per year for the UK 
economy.1 However, portrayed as an early hub for superspreading,2 
academic gatherings experienced a wave of  change due to the coronavirus 
(COVID-19) pandemic, with conferences and social distancing becoming 
mutually exclusive events.
Endocrinologists are integral to general medicine and occupy much of  
the COVID-19 frontline, with consultants returning to night shifts and 
trainees manning a 7-day NHS. As our working lives changed, learning also 
saw a ‘new normal’. COVID-19 dominated journals and filled teaching 
slots, whilst specialty training vaporised. However, excess deaths outside 
COVID-19 were becoming a worrying reality,3 serving as a reminder that 
training must go on, albeit differently. 
At Imperial College London, we wanted to continue with our 12th Annual 
Endocrine Masterclass 2020. However, we recognised that an overhaul in 
our approach to large face-to-face teaching forums was needed.
CONVENIENCE IS KEY
As reflected by the popularity of  Uber and Amazon, convenience influences 
decisions. Anti-social shifts, high sickness rates and clinicians working from 
home meant that convenience was key in securing an interested audience. 
We set up fortnightly bite-sized themed Masterclass sessions lasting 2 hours 
and divided into four subsessions. Each opened with a general overview, 
followed by case presentations from across the UK, and ended with expert 
discussions. These sessions were delivered via a Zoom meeting, easily 
accessible through any device with one click on a web link. Through regular, 
short sessions, we ensured numerous opportunities to attend with small 
fortnightly time commitments. Zoom also has the option to record sessions, 
so they could be watched ‘on demand’ later (www.imperialendo.com/
metmed).
FEATURE
WRITTEN BY RISHEKA WALLS, NIAMH MARTIN AND KARIM MEERAN
COVID-19
THE C WORDS:
CONFERENCES IN COVID-19  
conference noun. /ˈkα:nfərəns/ a large official 
meeting, usually lasting for a few days, at which 
people with the same work or interests come together 
to discuss their views. Oxford English Dictionary
social distancing trying to avoid close contact with 
anyone you do not live with. NHS England
Figure 1. Mentimeter questions with audience responses from a case presentation about Cushing’s disease. (a) A word cloud where the audience could 
free-type an answer to the question ‘Give one complication of Cushing’s’: the more popular an answer, the larger the font size. (b) Audience answers 
to ‘What test should we do?’ (c) Audience answers to ‘What test is next if low dose dexamethasone suppression test (LDDST) does not suppress?’ It 
was clear from the large number who chose high dose dexamethasone suppression test (HDDST) that this area needed more explanation, so we could 
spend more time on the evidence that a HDDST is not a good test, and that guessing the source of ACTH would actually be more accurate than an 
HDDST. (d) Audience answers to ‘Does this patient have Cushing’s disease?’
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the disease-relevance of  miR-mediated AR regulation. Post-transcriptional 
modulation of  AR activity by miRs is via altering transcript stability, 
translational efficiency and regulatory networks. 
Studies have identified a number of  miRs that directly target the AR, 
including the miR-30 family members, miR-30c-5p and miR-30d-5p, 
which were shown to have significantly reduced expression in metastatic 
CRPC (mCRPC) compared with healthy control tissues.4 However, 
direct AR-modulatory miRs not only act to suppress the AR but can also 
increase AR activity, sometimes functioning as oncomiRs. Data from our 
laboratory have shown that miRs-346 and 361-3p, both of  which directly 
bind the AR 3’UTR, increased not only the activity and expression levels 
of  the wild type AR, but also that of  AR-Vs, as well as promoting variant-
driven prostate cancer cell proliferation. This upregulation could provide 
a mechanism by which the cancer cells maintain AR activity even under 
androgen-depleted conditions.5
Regulation of  AR is not only achieved via the direct action of  miRs, but 
also by a wide variety of  protein factors, including co-repressors, co-
activators, and pioneer and transcription factors. At least 200 different 
co-regulators are known to regulate the AR, many of  which are themselves 
under miR control, thus constituting indirect miR regulation of  AR activity. 
For example, the AR co-repressor SHP is repressed by oncogenic miR-141, 
which shows increased expression in prostate cancer, with the net result 
being increased AR activity.6 In contrast, AR activity is repressed indirectly 
by let-7c targeting of  c-Myc, a transcription factor that positively regulates 
the AR gene.7 
FEATURECOVID-19 / ENDOCRINE CANCER
ANDROGEN RECEPTOR AND MICRORNAs
The androgen receptor (AR) is the critical driver of  prostate cancer growth, 
both in early hormone-responsive disease and in advanced prostate cancer. 
Thus, the first-line treatment is androgen-deprivation therapy (ADT). 
However, resistance to this therapy usually develops after 2–3 years. This 
results in the emergence of  lethal disease: so-called castration-resistant 
prostate cancer (CRPC). The mechanisms driving this progression remain 
largely unclear, although continued AR signalling despite depletion of  
circulating androgens is key, and may be partly driven by constitutively 
active AR variants (AR-Vs).
Notably, AR is the most microRNA (miR)-targeted oncogene in prostate 
cancer.1 MicroRNAs are small non-coding RNAs comprising around 22 
nucleotides that bind to complementary sequences most often present 
within the 3’UTR of  their target mRNAs, resulting in post-transcriptional 
regulation – usually, although not exclusively, negative. MicroRNAs can 
have oncogenic and/or tumour suppressive roles, with the potential to 
regulate a large number of  genes/gene networks and thus have significant 
impact on disease outcome. Excitingly, they are also hormone-like, in that 
they are seemingly released (actively or passively) by tissues, circulate in 
the blood and so have the potential to act at distant sites, resulting in their 
description by the term ‘hormomiR’.2,3
MICRORNA TARGETING AND AR REGULATION
Mapping of  miR:RNA interactions in prostate cancer cell lines has shown 
that, as well as being the most frequently targeted oncogene in prostate 
cancer, the AR is in the top 5% of  all miR-regulated genes,1 supporting 
REFERENCES
1. Business Visits & Events Partnership 2016 www.businessvisitsand 
eventspartnership.com/news/partnernews/488-visitbritain-launches-
programme-to-boost-international-business-events-across-the-uk.
2. Siddique H 2020 The Guardian www.theguardian.com/world/2020/feb/10/
super-spreader-brought-coronavirus-from-singapore-to-sussex-via-france.
3. Ratnasabapathy R 2020 BMJ 369 m1496.
WRITTEN BY SUE M POWELL, CLAIRE E FLETCHER AND CHARLOTTE L BEVAN
HORMONES AND HORMOMIRS:
MICRORNAs IN PROSTATE  
CANCER THERAPY  
Following the popularity of  our sessions, they have continued fortnightly, 
and we have run an insulin pump course and further metabolic medicine 
sessions. Our annual Imperial Pituitary Masterclass in September was 
also will also be delivered on Zoom. Such virtual interfaces cannot 
replace physical conferences but, by embracing both physical and virtual 
conferencing in the future, maybe these particular ‘C words’ aren’t all bad 
and, for learning, perhaps we can have our ‘C’ake and eat it.
RISHEKA WALLS (née RATNASABAPATHY), NIAMH MARTIN AND 
KARIM MEERAN
Specialist Registrar in Endocrinology, Diabetes and General Medicine 
and Honorary Clinical Research Fellow, Consultant in Endocrinology 
and Diabetes, and Professor of Endocrinology, Imperial College NHS 
Healthcare Trust and Imperial College London
a regular, accessible and inclusive conference with audience participation 
and empowerment of  those less vocal, with 75% wanting our sessions to 
continue beyond lockdown (Figure 2).
Figure 2. Reponses of 140 participants to the question ‘When COVID-19 is 
over, will Zoom be better than a day in the lecture theatre?’
Yes, I will be happy with whole  
Zoom instead of live lectures
No, once COVID-19 is over I  
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by downregulating the expression of  PDCD4, a known suppressor of  
tumorigenesis.14
Potentially, the identification of  the most critical miR(s) associated with 
drug resistance will be the cornerstone for the design of  therapeutics. To 
date, antagomiRs and miR mimics are two highly promising miR-based 
therapeutics. However, it is widely accepted that the effective, targeted 
delivery of  miR therapeutics is still a major challenge that needs to be 
overcome before these can be used extensively in the clinical setting. With 
much ongoing research in this area, it can only be a matter of  time before 
miR-based therapies, probably in combination with more traditionally 
hormone-cased therapies, are used in advanced prostate cancer.
SUE M POWELL, CLAIRE E FLETCHER AND CHARLOTTE L BEVAN
Department of Surgery and Cancer, Imperial College London
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MicroRNAs are known to be dysregulated 
in CRPC when compared with hormone-
responsive prostate cancer, with more 
decreased than increased at this later 
stage. CRPC-downregulated miRs often 
inhibit oncogenic processes such as 
proliferation, migration and invasion. 
An example of  one such is miR-145-3p, 
which functions as a tumour suppressor 
in prostate cancer by inhibiting cell cycle 
progression and survival through its 
targeting and downregulation of  genes 
such as MELK, BUB1 and CDK1, all of  




Expression of  alternatively spliced forms 
of  AR, known as AR-Vs, is an important 
mechanism of  ADT resistance. These 
variants lack the ligand-binding domain 
(LBD), and thus are constitutively active. 
Crucially, they are not responsive to ADT, 
since these therapies rely on the presence 
of  the LBD. Thus, modulation of  AR-V 
levels using miRs, including variant-specific miRs, may represent a novel 
therapeutic strategy for mCRPC. 
Studies have shown that certain miRs, for example miR-124, are able to 
target the transcripts of  both full-length AR and AR-Vs due to distinct 
binding sites within the 3’UTRs, and so lead to downregulation of  both full 
length and variant AR.9
AR-Vs have distinct 3’UTRs when compared with the full length transcript 
(as shown in the Figure), which is likely to account for the ability of  miRs to 
differently regulate them. The characterisation of  these distinct sequences 
may lead to further identification of  additional variant-specific miRs.
THERAPEUTIC POTENTIAL OF MICRORNAs
The challenge for all in the field of  cancer research is identifying new 
therapies that will reduce mortality and morbidity. Excitingly, miRs 
have several ideal therapeutic properties: they are small, relatively 
inexpensive to synthesise, highly target-specific, and have the potential to 
be modified in order to improve in vivo stability and cellular uptake. They 
also display disease and tissue specificity. Several clinical trials of  miR-
based therapeutics in cancer have been reported.10,11 The majority utilise 
synthetic, complementary oligonucleotides which sequester the target 
miR, inhibiting its function within the cell. Such ‘antagomiRs’ have been 
reported to be well tolerated, with no long term adverse effects, as seen in 
phase II trials of  anti-miR-122 and anti-miR-155.12
In support of  pursuing AR-associated miRs as therapeutic targets in 
prostate cancer, new evidence is emerging which suggests that aberrant 
expression of  miRs can modulate AR activity, including miRs-221/222. 
These were identified as upregulated in 90% of  mCRPC cases when 
compared with primary tumours. This altered expression affected how 
cells are able to respond to androgen treatment, thus suggesting potential 
involvement of  this miR family in the transition to CRPC.13 
Dysregulated miRs can also promote cell survival, proliferation and 
the development of  drug resistance. For example, increased miR-21 
levels in mCRPC may contribute to docetaxel chemotherapy resistance 
FEATURE ENDOCRINE CANCER
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Schematic representation of AR and AR-V transcripts, highlighting the differences in 3’UTR length 
between the canonical AR and the most commonly detected variants. Coloured regions represent 
different length 3’UTRs. CE, cryptic exon.
AR 3ˈUTR – 6.9 kb
AR-V7 3ˈUTR – 1.3 kb
AR-V1 3ˈUTR – 0.625 kb
AR-V4 3ˈUTR – 0.921 kb
AR-V9 3ˈUTR – 2.5 kb
AR-V567es 3ˈUTR – 8.5 kb
AR gene












1                                                                                        2                                                            4   5  678
1          23 4 5 678
1               2 3
1           23
1              2  3   3
1            2 3
1          23 4 8 9






1                    2 3
 THE ENDOCRINOLOGIST | AUTUMN 2020 | 9
independent cancers. Moreover, irosustat (a compound that I did much  
pre-clinical research on) has entered clinical trials and is now being 
considered for a range of  hormone-dependent malignancies. However, 
this drug development path has been fraught with difficulties, but is an 
interesting story of  the rollercoaster and sometimes brutal route from  
drug discovery to patient care.
Let’s start in 2004 when I joined Sterix Ltd, a spin-out company of   
Imperial College London, supported by Ipsen. It was my second 
postdoctoral position, and I had limited knowledge of  drug discovery or 
even steroids. The next few years rapidly reversed this ignorance.
Unfortunately, I cannot claim to having discovered and initially developed 
irusostat (also known as STX64 or 667Coumate), a highly specific, 
highly potent steroid sulfatase (STS) inhibitor. This honour goes to the 
inspirational team of  steroid biochemists Michael Reed and Alan Purohit 
(Imperial College London) and medicinal and biological chemist Barry 
Potter (University of  Bath, now University of  Oxford). 
STS catalyses the desulfation of  generally inactive sulfated steroids and thus 
is considered an important activating step for hormones. With regards to 
hormone-dependent breast cancer, the key steroid is oestradiol, which binds 
ERα to stimulate growth. Blocking oestradiol synthesis and action has been 
the cornerstone of  breast cancer therapy for over 40 years. Aromatase and 
STS both synthesise oestrogen from steroid precursors (see Figure) and so 
inhibition of  these pathways is an attractive therapeutic target.
NAVIGATING CLINICAL TRIALS
After preclinical success, irusostat was taken forward to a ‘first-in-class’ 
phase 1 clinical trial for patients with hormone-responsive breast cancer. 
Initial results were hugely encouraging, with a 5mg/kg oral dose of  
irusostat for 5 days resulting in 98–99% inhibition of  tumour STS activity 
and significant reduction of  serum levels of  oestrone (by 76%), oestradiol 
(by 39%), dehydroepiandrosterone (by 41%), androstenediol (by 70%), 
androstenedione (by 62%) and testosterone (by 30%). Importantly, 4 out 
of  the 14 patients recruited showed signs of  stable disease: no mean feat in 
these difficult-to-treat patients who had progress on standard therapies.1
Frustratingly, these initial promising results were somewhat undermined 
due to a poorly designed follow-up clinical trial that had limited input from 
the original scientific team who had identified irusostat in the first place. 
This second trial did not stratify patients and thus allowed all breast cancer 
patients, irrespective of  their hormone status, to be treated with irusostat. 
Consequently, treatment was significantly less effective when compared with 
the first trial which had focused only on ERα-positive breast cancer patients. 
This was a significant setback for the continued development of  STS 
inhibitors, and was a lesson on how poor planning can dent even the most 
robust drug development projects.
Irusostat received a further knock to its progress through another clinical 
trial, this time in patients with endometrial cancer. Irosustat performed 
The oestrogen metabolism pathway showing the importance of 
the enzymes steroid sulfatase (STS) and aromatase (AROM) in 
oestradiol synthesis. ERα, oestrogen receptor α; HSD, hydroxysteroid 
dehydrogenase.
‘Initial promising results were somewhat 
undermined due to a poorly designed 
follow-up clinical trial that had limited 
input from the original scientific team who 
had identified irusostat in the first place.’
FEATUREENDOCRINE CANCER
Breast cancer remains a significant NHS health 
burden here in the UK. Through inhibitors 
targeting oestrogen receptor α (ERα; tamoxifen), 
aromatase activity (anastrozole, letrozole), and 
HER2 (tratuzamab, pertuzamab), scientists have 
developed some impressive therapeutic advances. 
Despite this, there remains a worryingly high recurrence rate for many 
patients who have undergone chemotherapy and/or biotherapy. Indeed, 
ERα-positive breast cancer patients treated successfully with surgery and 
aromatase inhibitors still have an approximately 20% chance of  breast 
cancer recurrence. Thus, there remains an unmet need to develop new 
drugs to improve outcomes.
THE PATHWAY TO DRUG DEVELOPMENT
I have been fortunate to have been immersed in this research area for most 
of  my scientific career. Indeed, through my work and the collaboration of  
many others, I’ve seen most aspects of  the drug development of  various 
novel compounds that target both hormone-dependent and hormone-
WRITTEN BY PAUL FOSTER
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not dissimilar to that of  PDAC. Furthermore, around 60% of  patients 
present with metastatic PNETs, usually with liver metastasis, with a median 
survival of  only 24 months.
Surgery is the mainstay of  therapy for PNETs. However, this is often not 
curative due to advanced disease. Although currently available medical 
therapies have been shown to improve progression-free survival (surrogate 
marker for overall survival), many studies group PNETs with other types 
of  NETs due to their rarity, making specific inferences regarding PNET 
outcomes challenging. Therefore, there is a need for more effective 
targeted treatments, based on an improved understanding of  the molecular 
mechanisms that underpin the development of  PNETs.
PNET GENETICS AND EPIGENETICS
Approximately 10–15% of  PNETs occur as part of  an inherited  
syndrome, such as multiple endocrine neoplasia type 1 (MEN1), von 
Hippel–Lindau disease, neurofibromatosis type 1 and tuberous sclerosis 
complex 1 and 2. Of  these, MEN1 is the most common hereditary 
syndrome associated with an increased susceptibility to PNET  
development (approximately 10%). 
However, the majority of  PNETs are sporadic, with a low mutational 
burden. Nonetheless, large-scale whole genome and exome sequencing 
studies have shown that the mutations most commonly found in sporadic 
PNETs involve the genes MEN1, ATRX and DAXX, which are involved 
in the epigenetic mechanisms of  histone modification and chromatin 
Pancreatic neuroendocrine tumours (PNETs) 
represent a spectrum of cancers that arise from 
the islet cells of the pancreas. PNETs are rare and 
reportedly account for 3–5% of all pancreatic 
tumours, with an incidence of 1–3 cases per 
100,000 individuals per year. The incidence rate 
appears to be increasing. However, it is unclear 
whether this is a true increase or if it can be 
explained by improved detection on endoscopy 
and imaging.
Despite high profile cases, including Steve Jobs, Arethra Franklin and  
Irfan Khan, who have been diagnosed with and subsequently died from 
PNETs, there continues to be a lack of  awareness and understanding of  
these tumours among the general public, and the medical and scientific 
communities. This may partly be explained by the relatively good prognosis 
and slow-growing nature of  these tumours when compared with pancreatic 
ductal adenocarcinoma (PDAC), the most common type of  pancreatic 
cancer. 
However, a proportion of  PNETs (e.g. poorly differentiated neuroendocrine 
carcinomas) are highly aggressive, with a median survival of  <12 months, 
FEATURE
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Although I have now moved on from the further development of  irosustat, 
my own research laboratory still heavily focuses on these areas of  research, 
albeit in new, emerging ways. We have recently shown that STS inhibition 
may be beneficial in treating a subset of  colorectal cancer tumours that 
are oestrogen-responsive5 and we continue to develop novel STS inhibitors 
with excellent potency.6 Thus, there remain many new drug development 
avenues in this area that should see new inhibitors of  oestrogen metabolism 
playing an important role in cancer research for the foreseeable future.
PAUL FOSTER
Institute of Metabolism & Systems Research (IMSR), University of 
Birmingham
well, with an increased number of  patients with more stable disease 
(47%) compared with the current standard therapy (32%) – the progestin 
megestrol acetate (MA). However, overall, there was no statistically 
significant difference between the groups with regards to patient response or 
survival rates.2 Thus, the trial was halted early.
OVERCOMING SETBACKS
These setbacks made it increasingly challenging to garner support for 
STS inhibitors to advance further into clinical trials. But we had another 
therapeutic strategy up our sleeves that would help drive further irusostat 
clinical trials. This was the concept of  dual aromatase sulfatase inhibitors, 
or DASIs.
As part of  our company’s drug pipeline, we had been developing DASI 
compounds since the mid-2000s; these had shown excellent efficacy in 
preclinical models of  breast cancer.3 Targeting both aromatase and sulfatase 
was a no-brainer and provided interesting chemical entities and novel 
dual action efficacy. These studies informed the way forward: clinical trials 
overseen by Cancer Research UK to test irusostat in combination with an 
aromatase inhibitor (the IRIS trial). This trial reported in 2017 and showed 
evidence of  clinical benefit which underpinned the scientific concept of  
STS inhibition.4 Larger studies are now required, with further clinical 
development still on the cards.
REFERENCES
1. Stanway SJ et al. 2006 Clinical Cancer Research 12 1585–1592.
2. Pautier P et al. 2017 International Journal of  Gynecological Cancer 27 258–266.
3. Foster PA et al. 2008 Clinical Cancer Research 14 6469–6477.
4. Palmieri C et al. 2017 Breast Cancer Research & Treatment 165 343–353.
5. Gilligan LC et al. 2017 Journal of  Clinical Endocrinology & Metabolism 102 
4435–4447.
6. Moi D et al. 2019 European Journal of  Medicinal Chemistry 182 111614.
 THE ENDOCRINOLOGIST | AUTUMN 2020 | 11
5-methylcytosine (5mC), usually at the start of  the gene sequence 
(promoter). This ‘mark’ can either be maintained or removed during 
cellular replication, or it can be actively removed by the epigenetic  
eraser ten-eleven-translocase (TET) to form 5-hydroxymethylcytosine 
(5hmC). In opposition to 5mC, 5hmC protects the promoter site and 
enables gene transcription.
Unbalanced DNMT and/or TET activity may lead to 
inappropriately methylated/‘switched off’ tumour suppressor genes or 
hydroxymethylated/‘switched on’ oncogenes resulting in uncontrolled 
cellular proliferation.
TARGETING HISTONE MODIFICATIONS IN  
PNETs
Histones, which package and condense DNA, can be epigenetically 
modified through the addition of  methyl and/or acetyl marks to histone 
tails (read by epigenetic readers). This results in either an open/‘relaxed’ 
form (euchromatin), which enables gene transcription, or  
an inaccessible/‘closed’ form (heterochromatin). 
The bromodomain and extra-terminal domain (BET) proteins are  
a family of  epigenetic readers that bind to a specific type of  histone 
modification (acetylation) and recruit other proteins that regulate gene 
expression. Dysfunction of  the BET proteins has been linked to many 
cancers, through the upregulation of  cancer-related genes, such as  
c-MYC. 
Our group has previously shown that the BET inhibitor JQ1  
decreases proliferation in PNET cell lines and increases apoptosis of   
PNETs that develop in mice. However, the poor half-life and bioavailability 
of  JQ1 mean that it is unsuitable for clinical development. Novel  
BET inhibitors with improved selectivity and tolerability profiles have 
recently been developed. We are currently testing these and a panel of   
novel compounds (e.g. writers and erasers) in preclinical PNET models,  
to identify candidates that could be further developed for clinical use.
The variable efficacy and limited treatment options available for  
advanced PNETs presents a challenge for healthcare professionals,  
scientists and – most importantly – patients. In the current era of   
precision medicine, overcoming this challenge through an in-depth 
understanding of  the epigenetic 
mechanisms involved in PNETs  
and the investigation of  therapies 
that target these pathways may 
identify a novel treatment  
approach for these tumours.
KATHERINE A ENGLISH,  
OMAIR A SHARIQ AND  
KATE E LINES
Cancer Research UK Clinical 
Research Training Fellow, 
Clinical Research Fellow 
and Clarendon Scholar, and 
Oxford-Bristol-Myers-Squibb 
Research Fellow, Academic 
Endocrine Unit, University 
of Oxford, Oxford Centre for 
Diabetes, Endocrinology and 
Metabolism, Churchill Hospital, 
Oxford
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remodelling. Epigenetics (which literally means ‘above’ or ‘on top of ’ 
genetics) refers to changes in gene expression that are not caused by 
alterations in the underlying DNA sequence. 
Enzymes responsible for carrying out epigenetic modifications are  
known as ‘writers’, while those that remove modifications are referred 
to as ‘erasers’. Epigenetic ‘readers’ have the ability to recognise and 
bind to specific epigenetic modifications and recruit additional proteins 
that regulate gene transcription (Figure). In cancer, these mechanisms 
may be dysregulated, resulting in either upregulation of  oncogenes or 
downregulation of  tumour suppressor genes. Unlike genetic mutations, 
epigenetic changes are reversible, therefore drugs that target epigenetic 
mechanisms may represent a promising therapy for the treatment of  
PNETs.
In October 2019, we formed the Oxford NETs research team, within 
Raj Thakker’s lab at the University of  Oxford. The focus of  our group 
is to investigate different aspects of  epigenetics in NETs (including DNA 
methylation and histone modifications) as well as testing of  novel  
epigenetic-targeting compounds.
THE DNA METHYLOME OF PNETs
DNA methylation is essential for normal development through its ability 
to silence/‘turn off’ specific genes. This process is required for cellular 
differentiation and homeostasis.
In DNA methylation, DNA methyltransferase (DNMT; an epigenetic 
writer) adds a methyl group to the DNA base cytosine (C) to form 
‘There is a need for more effective 
targeted treatments, based on an 
improved understanding of the  
molecular mechanisms that underpin  
the development of PNETs.’





















The Society recognises that industry is a crucial part of the endocrinology community 
and through our Corporate Support scheme we commit to facilitating dialogue between 
professionals in industry, academia and clinical practice. In doing so, we can better represent 
endocrinology as a discipline, identify its challenges and find better healthcare solutions.
For further information, visit www.endocrinology.org/corporate or  
contact sophie.tovey@bioscientifica.com.
HRA Pharma Rare Diseases is dedicated to bringing the best 
care and services to patients and is committed to supporting 
healthcare professionals all over the world.
We have over 15 years’ experience in rare and ultra-rare 
diseases and are passionate about improving the lives 
of people affected by these conditions. We recognise 
that people living with rare diseases often have severe 
and potentially life-threatening disabilities that impact not 
only their quality of life, but also the lives of those who care 
for them. Delays in diagnosis, together with the lack of effective 
treatments are just some of the challenges faced by people living 
with a rare disease.
By partnering with the community, we are committed to tackling 
current challenges, reducing the time to accurate diagnosis, 
enabling global access to treatment and offering effective 
options for the long-term management of rare diseases. Our 
purpose is to improve the quality of life and the experience of 
care. We are confident that through innovative ideas, robust 
science and a passionate and highly focused team, we can 
elevate the needs of patients living with a rare disease 
and help to narrow inequalities in the standards of care 
across the globe.
Together we fight, so no patient is left behind!
For more information, contact Sara Elgott,  
Rare Diseases Country Lead UK & Ireland  
s.elgott@hra-pharma.com
        SOCIETY FOR 
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Pfizer is one of the world’s premier innovative 
biopharmaceutical companies, discovering, 
developing and providing over 100 different 
medicines, vaccines and consumer healthcare 
products that help save and transform the lives of 
millions of people in the UK and around the world 
every year.
For more than 25 years, Pfizer Endocrine Care 
has been committed to the advancement of 
endocrinology. This is demonstrated by our innovations 
in endocrine care: Pfizer UK was the first company to 
launch single-dose and multi-dose growth hormone (GH) 
delivery devices; it has built up the largest international 
databases of patients receiving GH therapy; and it produces 
the first and only GH receptor antagonist for the treatment of 
acromegaly.
The Society for Endocrinology has entered into a partnership level 
agreement with Pfizer. The agreement is first of its kind for the Society, and 
aims to deliver maximum benefit to both organisations and the broader aim 
of advancing endocrinology.
To find out more about what Pfizer are doing to support the NHS and patients in 





Tadworth KT20 7NS 
UK
Tel: +44 (0)1304 616161
Web: www.pfizer.co.uk
Paul Carroll, Chair of the  
Society for Endocrinology 
Corporate Liaison Committee, 
says  
“The partnership recognises 
the Society for Endocrinology’s 
commitment to working with 
industry to achieve its objectives. 
It represents a true collaboration 
with an industry partner, working 
on joint projects for the benefit 
of endocrinology.”
James Steed, UK Lead for 
Endocrine Care at Pfizer, 
comments  
“The NHS is changing in response 
to various pressures, and the 
needs of our partners and the 
people they care for reflect this. 
We believe that, through working 
in partnership, combining our 
skills, experience and resources, 
together we can tackle some of 
the greatest challenges facing the 
NHS today. The new partnership 
will strengthen Pfizer’s relationship 
with the Society, and ultimately 
improve patient care.”
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months have I taken back a modicum of  control and know when to ask the 
right questions and with whom to consult.
Cancer is wily and affects your life in many different ways, physically and 
psychologically. It is the silent, unseen psychological effects that are often 
overlooked and I would counsel anyone going through this difficult time to 
seek support, no matter how well they think they are doing. Not so long ago, 
it was enough to succeed in getting someone to stay alive for longer, but now 
we encounter people who are more likely to survive, and live a long time 
after cancer. Also, more and more people are living quite normal lives with 
cancer, which is a relatively new concept to be addressed.
MAKING THE DISCUSSION A PRIORITY 
I know that fertility treatment is constantly evolving. But I believe that a 
medical team have a responsibility to address the issue with a patient as 
early as possible during diagnosis and treatment, in order for the patient to 
have time to process whether it is going to be a priority or not. 
It goes without saying that a patient is overwhelmed by the information 
being thrust at them at this difficult time, but doctors need to give their 
patients a certain level of  trust, to realise that they have the right to decide 
the importance of  fertility in their future. I believe that a doctor has the 
responsibility to ‘plant the seed’ early on.
There is no need to overwhelm a newly diagnosed patient with all the 
options, as I know that it is an expert field. But ‘forewarned is forearmed’ 
and the right information could prevent a lot of  problems down the line. 
We tend to deal with the fallout from cancer on a reactive basis, rather than 
having the information in advance. 
Hopes and dreams are constantly changing, especially after a cancer 
diagnosis. Those who did not ever want children may suddenly long for 
them. They may divorce, remarry or want more children, or face many 
other life issues that we are presented with as human beings. What someone 
feels at 28 may be very different to what they may feel at 38 or 48. 
A patient/person deserves to be provided with the information that they 
need to make a considered decision.
CAROLINE MASLIN
Cancer concentrates the mind, but fertility isn’t 
your first thought when you receive a diagnosis. 
It is such an overwhelming time: you are at the 
complete mercy of your medical team and you 
want to protect the people closest to you. Your 
survival is paramount and it may only be on 
reflection, at a later date, that the importance of 
fertility can become something of a priority. 
When you are diagnosed with cancer at a relatively young age, fertility 
is most likely going to be an issue. Whether due to surgery or another 
treatment, it will have an impact one way or another.
MY STORY
I was diagnosed with breast cancer in 2012 at the age of  36. I underwent 
chemotherapy, a mastectomy and a course of  radiation. I was then put on 
the oestrogen inhibitor tamoxifen, which sent me into menopause by the 
time I was 38. In 2017, my cancer metastasised into my bones and lymph 
nodes but, after a successful course of  immunotherapy and lifestyle changes, 
I am now one of  those lucky ones ‘living with cancer’. I had children before 
my cancer diagnosis, but fertility was never addressed with me during my 
initial treatment. I was never asked if  I had children or if  I even wanted 
children, or if  I wanted more children. I feel that the doctor didn’t see it as a 
priority, which I can understand. But, after coaching others in the course of  
my voluntary work with a local cancer support network, it is very clear the 
loss of  fertility can have huge impact on patients. We put our trust in our 
medical teams, but that leads to a loss of  control on the patient’s part, which 
can have huge repercussions.
FERTILITY: AN OVERLOOKED ISSUE
Eight years down the line of  treatment, and after supporting many clients 
through my voluntary work, it’s clear that the issue of  fertility is something 
that is often overlooked or deemed unimportant at the time of  diagnosis 
and treatment. Even when I did go through a period of  serious reflection 
later on in my treatment, wishing I could have more children, it was a ‘fait 
accompli’ and I had to move on. I never talked to anyone, even my family 
and friends, about it. I am not alone in experiencing this. Only in recent 
FEATURE
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CANCER AND FERTILITY:
A PATIENT’S PERSPECTIVE  
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Caroline’s elegant description raises many of  the major issues underlying 
the provision of  fertility preservation. Women with breast cancer 
constitute the largest diagnostic group facing fertility-damaging treatment, 
and those with hormone-sensitive disease have the additional issue of  
adjuvant endocrine treatment, with ovarian suppression for 5–10 years 
thereafter. 
Not all women will lose their fertility with cancer treatment, but the 
overall reduction in the chance of  a post-treatment pregnancy for women 
aged under 40 is 38% across all diagnoses. For women with breast cancer, 
the hazard ratio for achieving a first pregnancy after treatment is 0.30.1 
The need to address this issue with cancer patients before treatment starts 
was highlighted by NICE guidelines in 2013.2 The most relevant medical 
procedure, oocyte vitrification after ovarian stimulation, is now well 
established, although funding for adequate provision is a major challenge. 
Effective care requires rapid lines of  communication between oncology 
and reproductive medicine centres, as time will be of  the essence, and 
challenges the need for adequate information provision. Online decision 
aids (e.g. www.cancerfertilityandme.org.uk) may help here. 
New quicker protocols for ovarian stimulation have been developed based 
on a ‘random start’, rather than being limited to specific stages of  the 
menstrual cycle. Data on outcomes are limited; while there are emerging 
data that oocyte quality may be slightly reduced in women with cancer, 
good live birth rates can be achieved.3 
Caroline also raises the wish of  many women who already have children 
to have more after diagnosis – the natural desire to complete their family. 
This contrasts sharply with NHS-funded assisted reproduction, which 
limits treatment to a first child.
RICHARD ANDERSON
MRC Centre for Reproductive Health, University of Edinburgh
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2. NICE 2013 Fertility Problems: Assessment & Treatment CG156 
www.nice.org.uk/guidance/cg156.
3. Cobo A et al. 2018 Human Reproduction 33 2222–2231.
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Where next after ‘biggest and best’?  
PUBLIC ENGAGEMENT WITH SCHOOLS
simulator (who can only be described as an inflexible 75kg dead weight) will 
always be remembered by the Kingston team for our attempts to get him in 
and out of  the back seat of  my car for the event.
The schools’ afternoon at the annual Society for Endocrinology BES 
conference has proved to be a great way to engage and inspire a future 
generation of  endocrinologists. We are grateful to all the members who 
have volunteered each year to make it such a success. Visiting pupils and 
teachers have always been very positive, describing the event as fun and 
very educational, where they have learnt a lot about potential future careers.
WHERE NEXT?
Despite this great success, there are now questions around the future 
direction of  such public engagement events at a time of  social distancing. 
Just 4 months on from SfE BES 2019, the UK was placed in COVID-19 
lockdown and, even with lockdown gradually easing, it’s hard to imagine the 
complete return to such an intense face-to-face and highly interactive hands-
on format in the foreseeable future. 
In the short term, there has been the cancellation of  many planned events, 
as the sector re-orientates itself. One casualty was Clinical Update (now 
postponed from April 2020), where Heather Lampard (Society Careers and 
Engagement Officer) and I had already planned the public engagement 
training session for the day of  the Career Development Workshop. Another 
personal loss was the Big Bang Fair at Kingston University (scheduled for 
June), with great plans to work with the Society and present the ‘human cell 
signalling relay’ and ‘make your diagnosis’ again.
FUTURE OPPORTUNITIES
New challenges present new opportunities. I recall conversations before 
COVID with teachers at Brighton, regarding their disappointment in having 
to choose between the students to bring and those to leave behind, due to 
limited availability at the venue for each school. There is the need to consider 
broadening reach, being more inclusive and flexible and perhaps not always 
tying down events to selected venues, spaces and time constraints. Certainly, 
in the immediate future, the online world offers many new possibilities but, 
even then, we will have to learn to deliver our message very differently!
NIGEL PAGE
Public Engagement Committee
Endocrine Ambassador, Kingston University London
The next application deadline for the Society’s Public Engagement Grant is in March 
2021. See www.endocrinology.org/grants-and-awards/grants/
public-engagement-grant for more details.
Last November, the Society for Endocrinology 
held what was described as its ‘biggest and best’ 
public engagement event for schools. 
Since 2017, this initiative has become an established and distinctive part of  
the annual Society for Endocrinology BES conference. It provides school 
pupils with the opportunity to join delegates for a dedicated afternoon of  
insights into the world of  endocrinology. Revealing the everyday face of  the 
specialty, the event included opportunities to engage in hands-on interactive 
activities, and to meet the scientists, nurses and doctors who make up the 
Society’s membership.
I have always been passionate about creating inclusive scientific 
communities. Therefore, it has been a natural and proactive step to work 
within the Society to bring endocrinology to a wider audience, including 
pupils, who would not normally have the opportunity to experience such 
events. Consequently, I have had the pleasure to lead the organisation of  the 
last two schools’ public engagement events, in Glasgow (2018) and Brighton 
(2019).
STEPPING UP FOR BRIGHTON
After Glasgow, Brighton was always to be a ‘step up’, with the support of  
outreach representatives from the two local universities and the STEM 
ambassador hub. We had a phenomenal response: over 100 pupils (14–16 
years) and teachers from local schools wanted to attend. The location was 
also fantastic, as we had the large restaurant lounge at the Brighton Centre 
to work in, directly overlooking the seafront. Visualising the space and how 
it could be utilised is an essential part in planning any public engagement 
event. Along with the perfect place to set up an auditorium for the 
introductory ‘live’ show and the concluding Q&A session, we had a great 
networking area to position the tables and poster boards for the hands-on 
activities.
I opened the conference with an interactive presentation on ‘you and 
your hormones’, which of  course had plenty of  fake blood on hand, to 
demonstrate the main way hormones are transported around the body! 
Other props included Christmas tree lights with a ‘Post-it’ race to help 
express the different ways and speeds chemical messengers are transmitted 
around the body. Afterwards, there was the opportunity for everyone to 
get involved in the hands-on activities. The pupils also alternated between 
networking sessions to meet and talk directly to the scientists, doctors and 
nurses about their careers and what they really do.
This year, we encouraged activities that showcased the fantastic ideas 
members had developed through the Society’s Public Engagement Grant 
(www.endocrinology.org/grants-and-awards/grants/public-
engagement-grant). One, from King’s College London, was their ‘islet 
transplantation skills’ activity, which included 3D printed endocrine organs. 
Other activities included a ‘human cell signalling relay’ demonstrating what 
happens when a hormone delivers its final message to a cell and what can 
go wrong. This presented a fun way for pupils to learn about cell signalling 
and cancer, using energy sticks and plenty of  balls. I developed the relay last 
year for Glasgow, but it was the enthusiasm of  Kgabolele Manyathela (one 
of  Kingston University’s biochemistry undergraduates) in delivering it that 
no doubt led to it being polled the most enjoyable activity by visiting pupils.
With help from Vas Chortis (University of  Birmingham), I also developed 
‘make your diagnosis’. This lets pupils take on the role of  a doctor 
gathering clues about patients’ symptoms. It required taking vital statistics 
and interpreting some blood test results for thyroid disease to learn the 
impact hormones can have in making people ill. Hal, our fully sized patient 
The Q&A panel.
‘Make your diagnosis’: where pupils become doctors for the afternoon.
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Connecting the endocrine community is more important than ever, which is why we invite you to join 
us at SfE BES Online from 16-20 November 2020. This stream-lined, digital conference will bring the 
latest developments in endocrinology direct to your screens, including the much loved ‘What is new?’ 
session, Medal Lectures and an in-depth look at the Future of Endocrinology post-COVID-19. Content 
will be available on demand for all registered delegates, so you can view at a time which suits you. 
The new SfE BES digital platform also offers opportunities to network and discuss developments in 
endocrinology, including live Q&A sessions with speakers and colleagues.
You must register in advance to access the CPD accredited programme and all on-demand content. 
Register now to secure your place
www.endocrinology.org/sfebes2020/registration
Join or renew your membership
www.endocrinology.org/membership/join-or-renew
Each day, SfE BES Online will offer an opportunity for one or more Endocrine Network to gather in a 
dedicated session organised by Network Convenors. These sessions will highlight key updates within 
the networks, as well as facilitate discussion time for all participants.
Endocrine Network topics: 
• Adrenal and Cardiovascular
• Bone and Calcium 
• Endocrine Consequences of Living with and Beyond Cancer
• Endocrine Neoplasia and Cancer
• Metabolic and Obesity
• Neuroendocrinology
• Reproductive Endocrinology and Biology
• Thyroid
INTRODUCING SfE BES ONLINE
REGISTRATION IS FREE FOR MEMBERS 
OF THE SOCIETY FOR ENDOCRINOLOGY
ENDOCRINE NETWORKS
For further  





TO ADVANCE  
SCIENCE AND  
HEALTH
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Professor Robert Lefkowitz New York, USA
The SfE BES Online programme includes the much anticipated 
Presidential Lecture from Nobel Laureate Professor Robert 
Lefkowitz. Professor Lefkowitz is best known for his ground-
breaking discoveries revealing the inner workings of an important 
family of G protein-coupled receptors, for which he was awarded 
the 2012 Nobel Prize in Chemistry with Professor Brian Kobilka. 
The Presidential Lecture will focus on G protein-coupled receptors 
(GPCRs) molecular signalling and related pharmacology. 
MEDAL AND PRIZE LECTURE 
HIGHLIGHTS
Enjoy an exciting programme of the following 10 Medal and Prize 
Lectures:
Dale Medal Lecturer 
Professor Dame Frances Ashcroft Oxford 
Metabolic regulation of insulin secretion in health and disease
Society for Endocrinology Medal Lecturer 
Professor David Ray Oxford 
Circadian control of inflammation and metabolism
Starling Medal Lecturer 
Professor Davide Calebiro Birmingham 
Illuminating hormone receptors in physiology and disease
International Medal Lecturer 
Dr David Mangelsdorf Texas, USA 
FGF21 and nutrient stress: eat and drink, but don’t get too merry
Transatlantic Medal Lecturer 
Dr Daniel Drucker Toronto, Canada 
Incretins and cardiometabolic disease – an inflammatory 
perspective
European Medal Lecturer 
Professor Nelly Pitteloud Lausanne, Switzerland
Jubilee Medal Lecturer  
Professor Anne White Manchester 
POMC peptides: master regulators of the stress axis and 
neuroendocrine pathways in energy balance
CET Visiting Professor Lecturer  
Professor Mirjam Christ-Crain Basel, Switzerland 
New diagnostic and therapeutic options in vasopressin-dependent 
fluid disorders
Clinical Endocrinology Trust Lecturer  
Professor Fredrik Karpe Oxford 
Endocrine determinants of human fat distribution 
British Thyroid Association Pitt-Rivers Lecturer  
Dr Frederic Flamant Lyon, France 
Thyroid hormone and the timing of cortical circuits maturation
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LEARNING IN LOCKDOWN: 
LAB IN YOUR LIVING ROOM 
WEBINAR SERIES
OPINION
early career researchers how to use it for their own research. I also felt 
there was a gap that these webinars could fill: lots of  societies were setting 
up seminars using the traditional model in which someone presents their 
research, and I was conscious of  avoiding overlap. Many junior researchers 
were already anxious enough about losing research time and not having 
enough data, so seeing someone’s amazing data wouldn’t be beneficial to 
them. 
Mark: It has seemed that there has been a wave of  webinar series set up 
around the world, often with daily seminars being presented by leaders 
in their respective fields. It’s been a great opportunity to expand our 
knowledge into different areas of  research. At the same time, it’s also been 
the chance to ‘upskill’ as several postgraduate students and early career 
researchers have got to learn new ways of  analysing data or generating new 
findings from existing and publicly available datasets.
 
WHY DID YOU THINK THESE TOPICS WERE THE  
MOST IMPORTANT?
Caroline: I wanted them to be as accessible as possible to everyone. I 
realise not everyone has large amounts of  funding, so I suggested topics that 
could use existing data and be analysed using freely available software. We 
tried to come up with topics that would be relevant to as many people as 
possible, while trying to incorporate cutting-edge techniques. 
We invited early career researchers to present, as I felt more people would 
engage in the Q&A session, and because these are the people who are 
actually doing the laboratory work.
Mark: I think these were the areas that researchers could get the most 
out of  initially, and begin to use them as part of  their research projects. 
Being able to analyse datasets which were publicly available or to start to 
learn about the fundamentals of  techniques like CRISPR-Cas9 and RNA 
sequencing was beneficial.
HOW DO YOU THINK THE SHUTDOWNS WILL  
AFFECT YOUR RESEARCH LONG-TERM?
Caroline: For me, the next few months will be particularly challenging. 
How will we teach new students within the lab while maintaining social 
distancing? Will our new students feel supported and part of  the team? 
Adapting how we work will be important to address these challenges. If  
we are to take positive points from this period, it is that we are lucky to 
have technology that allows us to keep in contact, and it is possible that 
organisations will be more willing to accept flexible working patterns in the 
future.
Caroline Gorvin (Birmingham)  
and Mark Turner (Coventry)  
were instrumental in the 
development of the Society’s 
Research Skills: Lab in 
your Living Room webinar 
series – aimed at early career 
researchers locked out of their 
labs (accessible via the Members’  
Area of the Society website at  
www.endocrinology.org).
Here they describe the  
series’ inception and aims,  
and how research has been 
affected during the COVID-19 
lockdown.
HOW HAS THE LABORATORY SHUTDOWN  
AFFECTED YOUR RESEARCH?
Caroline: My research is entirely lab-based, so the shutdowns had a large 
impact on my work. This meant accepting that those last few experiments 
for fellowship applications were not going to happen. I spent all of  
lockdown writing: fellowship applications, a chapter and a review. Having a 
concentrated period of  time to focus on this was beneficial as, ordinarily, I 
get preoccupied with lab work.
 
We returned to our labs in July. It’s very different – now we work in shifts 
and maintain social distancing – but it is nice to be back. It has meant I 
have restructured my time to have lab-focused days and at least 1 day a 
week working from home.
Mark: Having recently started at Coventry University, I had only just 
managed to get my research underway when the laboratories shut down. 
While it has been frustrating not having access to the labs to conduct the 
experiments, it has given me the opportunity to think more about the 
experiments I need to do when the labs are back running. Away from the 
lab, and like most people, the shutdown has given me the opportunity to 
write or finish off papers and apply for internal and external funding.
WHY DID YOU WANT TO GET INVOLVED IN THE 
RESEARCH SKILLS SEMINARS?
Caroline: As it wasn’t too long since I was a post-doc, I could relate to 
how difficult it would be for many early career researchers working at 
home. As a lot of  data are now online, there was an opportunity to teach 
‘We returned to our labs in July. It’s very 
different – now we work in shifts and 
maintain social distancing.’
‘It’s been the chance to “upskill” as several 
postgraduate students and early career 
researchers have got to learn new ways of 
analysing data or generating new findings 
from existing and publicly available 
datasets.’
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Mark: From a practical standpoint, I’m fortunate that the majority 
of  my research is based in vitro and, while it’s frustrating to have to stop 
work because of  shutdowns, it might not affect my research as much 
as researchers from other disciplines. However, if  local lockdowns are 
announced with little warning, as we’ve seen recently, it is going to be 
a challenge to manage this without it causing significant disruption to 
research. 
What are likely to be affected are funding opportunities, which undoubtedly 
will become more competitive, both in terms of  the number of  applications 
and the funding available. 
WHAT OTHER RESEARCH SKILLS TOPICS WOULD 
YOU LIKE TO INCLUDE?
Caroline: We discussed several other topics, including analysis of  
microscopy images and statistical analysis. It would be great to hear from 
early career researchers to find out what they would like to learn (via 
media@endocrinology.org).
Mark: I’d like to see image analysis. Images can give you a lot of  
information about your samples, which can be used to generate interesting 
and potentially useful data. I think it would be great to find out what 
applications and approaches can be used to get the most out of  microscopy.
ILDEM AKERMAN University of Birmingham 
Differential gene expression analysis from RNA- 
sequencing data 
FABIO SANNA University of Oxford 
Publicly available data sources, a practical  
example
STUART MORGAN University of Birmingham 
Genetic screens and functional genomics using  
CRISPR-Cas9 technology
TORYN POOLMAN University of Oxford 
Data analysis using R
INÊS CEBOLA Imperial College London 
Analysis of  genetic association data with publicly  
available datasets
You can watch the Lab in Your Living Room series by logging into the Members’ Area at www.endocrinology.org.
If you would like to present a webinar or suggest a topic, email media@endocrinology.org.
WATCH OUR CLINICAL SKILLS WEBINAR SERIES 
These interactive sessions are free to Members and provide essential 
knowledge for trainees and recently appointed consultants in 
endocrinology and diabetes. The talks, delivered by experts, focus 
on selected topic areas to compliment learning for the MRCP(UK) 
Specialty Certificate Examination in Endocrinology and Diabetes this 
year. They are also indispensable for continued training of clinicians  
and nurses at all career stages.
Topics include:
• Cushing’s syndrome • Adrenocortical tumours/cancer
• Genetics of pituitary tumours • The infertile couple: anovulation/azoospermia
• Management of the transgender patient • Metabolic bone disease
• Thyrotoxicosis, thyroid eye disease & amiodarone-induced thyroid disease
Catch up with the series in the comfort of your own home by logging into the Members’ Area at  
www.endocrinology.org/members.
NEW ONLINE TRAINING FOR ENDOCRINE NURSES 
This series is free to members and will be available on demand too.
Topics include:
• Adrenal insufficiency • Diabetes Insipidus
• How to set up a nurse-led clinic • Medicolegal aspects of nurse-led training
WEBINAR TOPICS AND PRESENTERS
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Challenges for implementation of  preventive, diagnostic and treatment 
measures to the community have been magnified in the COVID-19 
pandemic, some of  which have been highlighted by recent ERC 
publications. One example has been the difficulty in the consistency 
of  mask-wearing due, in part, to shortages of  materials, inadequate 
distribution systems, and cultural and social barriers. Simultaneously, social 
justice issues have also moved to the forefront of  the public consciousness. 
The Black Lives Matter movement in the USA has energised the larger 
population against racial and ethnic inequalities following multiple well-
documented tragedies. 
One consequence of  this social movement has been greater recognition 
that socially disadvantaged populations fare worse from COVID-19 and 
have unique barriers to implementation. Social determinants of  health 
impact the outcomes from nearly all diseases worldwide, including diabetes 
and obesity, breast cancer, prostate cancer and others that are highly 
relevant to ERC. Several of  these diseases disproportionately affect specific 
ethnic and racial minorities, independent of  social disparities. ERC has 
an established interest in supporting research designed to understand the 
biological mechanisms for racial and ethnic differences in endocrine cancer 
frequencies and outcomes. Implementation and population science applied 
to diverse worldwide communities are areas of  further emphasis for ERC.
Journals such as ERC provide an opportunity to expand the scientific, 
racial, gender and ethnic diversity not only of  research, but also of  
researchers in the field. In addition to continuing to emphasise science 
relevant to healthcare disparities, we will be establishing early career 
pathways for peer reviewers and early career positions on the Editorial 
Board, with close attention paid to diversity. 
The COVID pandemic and current social climate have served to 
emphasise the importance of  the current strengths and future directions 
of  ERC. Continued emphasis on high quality science, enabling 
communication to the community, and continued and expanded attention 
to diversity, will all be needed as we move our field forward together. I look 
forward to working with our editorial team and with all of  you in achieving 
our mutual goal to improve the health of  all individuals with endocrine 
cancers.
MATTHEW D RINGEL
Division of Endocrinology, Diabetes and Metabolism, and Cancer 
Biology Program, The Ohio State University Wexner Medical Center, 
and The Ohio State University Comprehensive Cancer Center, 
Columbus, OH, USA
Having served previously as an ERC Associate Editor, as well as publishing 
in the journal and reading numerous outstanding high quality articles 
over the years, I am particularly excited to begin my new role. I am eager 
to work with the ERC Editorial Board, Bioscientifica, the Society for 
Endocrinology and the affiliated societies in continuing and expanding 
upon the work of  my predecessors.
When I was asked to write this opinion piece for The Endocrinologist to begin 
my tenure, I thought deeply about the timing of  this new role in the context 
of  the COVID-19 pandemic and the international responses to current 
social and racial tensions in the USA.
The COVID-19 pandemic and its rapid spread throughout the world 
have impacted on our core social fabric. It has enabled new international 
collaborations, but also has exposed deep social divisions within our 
communities. At no time since the early days of  the AIDS epidemic has 
biomedical research had such immediate impact on public policy and global 
public health. The critical importance of  rigorous basic, translational, 
clinical and population science cannot be overstated. 
Over the past 8 months, landmark studies have characterised key 
mechanistic elements behind SARS-CoV2 infection, enabled a deeper 
understanding of  the molecular epidemiology of  the disease, established 
preventive and life-saving clinical strategies, and developed new therapeutic 
compounds and vaccines with a joint goal to prevent and treat COVID-19. 
The pace of  this work has been breathtaking, and its importance is crucial 
to control the virus. It is also clear that the impact of  the research relies on 
successful implementation of  the findings to the community. For example, 
vaccine effectiveness will depend not only on its efficacy in rigorous clinical 
trials, but also on production of  adequate doses, cost management and 
individual adherence to vaccination recommendations.
There also have been important lessons to learn from errors that have 
slowed implementation of  the best new science. These have included 
publication of  manuscripts that were subsequently retracted and public 
policy decisions based on peer-reviewed but unconfirmed small data series, 
identified and popularised on social media. These experiences emphasise 
the crucial roles that scientific journals and peer review play as arbiters of  
rigorous science. Journals also can assist with communicating appropriate 
interpretations and conclusions to the general public. 
The urgency of  rapid translation of  science in the current situation is  
clear, and clarifies the need for a timely, rigorous and fair peer review 
process. Be assured that the high scientific expectations and outstanding 
peer review maintained by ERC’s authors, peer reviewers and editors  
will be continued, with a renewed commitment to enhance accurate  
and timely communication of  key results to the scientific and lay 
communities.
Outstanding science is necessary, but not sufficient, to ensure translation 
into clinical research and, eventually, public policy. As an international 
journal, ERC seeks to support research in all aspects of  endocrine oncology, 
including fundamental basic science, translational studies and clinical 
research, with an ultimate goal to improve the health of  diverse populations 
worldwide through new discovery. 
ENDOCRINE-RELATED CANCER: 
PRESENT CHALLENGES AND  
NEW OPPORTUNITIES
‘Journals such as Endocrine-Related 
Cancer provide an opportunity to expand 
the scientific, racial, gender and ethnic 
diversity not only of research, but also of 
researchers in the field.’
WRITTEN BY MATTHEW D RINGEL
It is an honour to be selected as the incoming Editor-in-Chief of Endocrine-Related Cancer (ERC). 
Following in the footsteps of Charis Eng is a daunting task. She and her team have done an 
outstanding job for the past 8 years in expanding ERC’s well-deserved reputation as a top flight  
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New NHS Steroid Emergency Card 
AVAILABLE TO ORDER
There will be 3 ways of obtaining a card:
• Through community pharmacies – for patients with known adrenal 
insufficiency who have had the necessary patient education, or need a 
replacement card; patients may wish to show a clinical letter or similar, 
but that is not essential.
• From GPs when having a routine review, if  primary care is managing 
steroid replacement.
• From hospital teams at next routine appointment.
The card can also be downloaded as a PDF, and added as a lock screen to 
mobile devices. Learn more from the Addison’s Disease Self-Help Group 
(www.addisonsdisease.org.uk). 
The new card can be ordered through the usual NHS ordering 
mechanisms:
• Secondary Care: Xerox online portal www.nhsforms.co.uk.  
You may need to raise a non-catalogue requisition in Oracle, selecting 
supplier as Xerox, and we can process the requisition by raising the 
order with NHS Forms. The cost is £2.65 (excluding VAT) for 100 
cards (one unit is 100 cards).
• Primary Care: PCSE online portal https://secure.pcse.england.
nhs.uk/_forms/pcsssignin.aspx.
Our adrenal crisis web page is a source of  all the relevant information, 
including published guidance, a downloadable PDF of  the card and links to 
patient educational resources. The QR code on the card goes directly to the 
adrenal crisis web page (www.endocrinology.org/adrenal-crisis). 
DR HELEN SIMPSON
Society for Endocrinology and RCP Patient Safety Committee
As you know, the new NHS Steroid Emergency 
Card is an NHS-wide card supported by our 
recently published guidance (www.rcpjournals.
org/content/clinmedicine/20/4/371).
We know many GP and hospital appointments are operating as telephone 
clinics for the time being. Hence, community pharmacy teams will initially 
issue most of  these cards, whilst we are working within COVID-19 
contingency plans.
A National Patient Safety Alert1 has been issued asking providers 
to ensure all eligible patients with adrenal insufficiency are issued with 
an NHS Steroid Emergency Card,2 to support early recognition 
and treatment of  adrenal crisis in adults. The alert requires that 
processes are put in place to check if  a patient has a card ahead of  any 
emergency treatment, elective surgery, or other invasive procedures. 
Our teams will have a key role in ensuring there are processes and 
systems within their institutions to fulfil these actions and support 
organisations in implementing local policies to ensure the safety of  our 
patients with adrenal insufficiency, as well as in providing teaching to 
other teams. Thank you for getting involved and thank you to all who 
have supported this work.
1. National Patient Safety Alert: www.england.nhs.uk/2020/08/steroid-
emergency-card-to-support-early-recognition-and-treatment-of-adrenal-
crisis-in-adults.
2. NHS Steroid Emergency Card: www.endocrinology.org/media/3703/
new-nhs-emergency-steroid-card.pdf.
Innovative clinical practice?  
YOUR SOCIETY NEEDS  
YOUR HELP!
relation to this, the Society have formed a working group that is examining 
the ‘Future of  Endocrinology’. It aims to share best practice and to truly 
take a step back and question how services may be best configured. We are 
working to tight time frames to ‘capture the moment’ and see what can be 
done differently. 
One part of  this activity is to gather innovative service ideas as a central 
resource that may then be shared across the UK for the betterment of  
patient care. It is possible that you have developed something that is either 
simple or obvious to you, and assume that everyone else must be doing the 
same, but this is not always the case. 
So, what can you do? Simply think of  the three clinical service innovations 
of  which you are either the proudest, or that has had the biggest impact for 




On behalf of the Society’s Future of Endocrinology working group
Send your thoughts to clinical@endocrinology.org for 
consideration by the working group.
So much has happened over the last six months. 
The COVID-19 crisis has taught us much about 
adapting rapidly and effectively to maintain clinical 
care for our patients. Even before the crisis many 
centres around the UK had developed novel and 
innovative ways of working for the benefit of 
patients. 
All too often, though, whilst such advances may have been implemented 
locally to good effect, their potentially broad application may not have been 
realised in the wider endocrine community. It is here that as a member of  
the Society you have the opportunity to make a real difference.
Steve Ball’s article (page 26) succinctly lays out a whole variety of  issues 
pertaining to clinical care in Specialised Endocrinology in this new era. In 
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WRITTEN BY INÊS CEBOLA
Transcriptional enhancers can 
regulate one or more genes at 
varying distances and irrespective 
of  their relative position (i.e. 
they can regulate genes either 
up- or downstream of  them). In 
practice, the complex nature of  
transcriptional enhancers has 
hampered the identification of  
true diabetes risk effector genes 
and the translation of  T2D 
GWAS variants into targeted 
therapies.
To address this problem, we 
applied promoter capture Hi-C6 
to create a genome-wide map of  
promoter–enhancer interactions 
in adult human pancreatic islets.7 
Using this approach, we identified target genes for approximately 80% 
of  all active human islet enhancers (36,664 of  45,683 enhancers). More 
specifically, this map enabled the systematic identification of  genes that  
are regulated by enhancers carrying T2D risk variants. We observed that 
T2D variants often interact with more than one gene and that, unlike 
what has been assumed until now, the nearest genes are not always the true 
targets of  T2D susceptibility variants. Indeed, over 75% of  loci with at 
least one T2D risk variant in an islet enhancer were assigned to novel target 
genes. 
These results have major implications for the interpretation of  past and 
future genetic signals identified in GWAS, as it is often assumed that GWAS 
variants are flagging the nearest gene. By bypassing the genome’s linear 
representation which is more commonly used, and putting genetic risk loci 
in the context of  the genome’s 3D conformation, we have gained access to a 
collection of  new putative diabetes risk effector genes.
We decided to validate our in silico predictions using CRISPR-Cas9 
perturbations in a human pancreatic b cell in vitro model. To this end, we 
first inspected the epigenomic landscape of  the human pancreatic b cell line 
EndoC-bH38 by performing an assay for transposase-accessible chromatin 
using sequencing (ATAC-seq9) to profile all accessible chromatin regions 
in the genome, a proxy for active and regulatory sequences. Our analysis 
revealed that EndoC-bH3 cells recapitulate the epigenomic landscape 
FEATURE
UNRAVELLING NEW TYPE 2 DIABETES REGULATORY 
LINKS WITH 3D CHROMATIN TOPOLOGY ANALYSIS AND 
CRISPR-Cas9 PERTURBATIONS
FROM OUR 2019 SCIENCE EARLY CAREER PRIZE LECTURER
Genome-wide association studies (GWAS) have identified over 300 loci in the human genome 
harbouring genetic variants that alter type 2 diabetes (T2D) risk.1,2 In the last decade, it has become 
clear that T2D genetic risk variants are enriched within transcriptional enhancers that are active in 
pancreatic islets,3–5 indicating that T2D genetic risk is underlined by defects in islet gene regulation.
Enhancer 
SNP
Assigned genes Genes affected by CRISPR CRISPR/Cas9 validations
CRISPRi CRISPRa Deletions
rs11257655 CAMK1D, OPTN CAMK1D, OPTN ✓ ✓ ✓
rs4237150 RFX3, RFX3-AS1, GLIS3 GLIS3 ✓ ✓ ✓
rs7903146 TCF7L2 TCF7L2 ✓ ✓ ✓ 
rs7163757 C2CD4A, VPS13C C2CD4A, VPS13C, C2CD4B ✓ ✓ NT
rs1401419 CRY2, PHF21A CRY2 ✓ ✓ NT
rs12189774 VEGFA VEGFA ✓ ✓ NT





rs58692659 MDGA, ZFAND3 MDGA1, ZFAND3 ✓ ✓ NT
Figure 1. Summary of enhancer perturbations performed in this study to validate T2D enhancer variant-to-
target-gene assignments (see also Miguel-Escalada et al. 20197). CRISPRa, CRISPR activation; CRISPRi, CRISPR 
inhibition; NT, not tested; SNP, single nucleotide polymorphism.
Figure 2. Islet promoter capture Hi-C (pcHi-C) analysis 
defines gene targets of enhancers bearing T2D-
associated variants near CDC123/CAMK1D. (a) The 
only T2D risk credible set variant that maps to an islet 
enhancer in the locus (rs11257655, zoomed inset) is 
assigned to CAMK1D and OPTN (dashed horizontal 
lines). Islet pcHi-C virtual 4C representations from 
pooled samples show interactions stemming from both 
CAMK1D and OPTN promoters towards rs11257655 
with ChICAGO>3, but not from CDC123. (b) CAMK1D 
and OPTN mRNA are regulated by the rs11257655-
containing enhancer. We deleted the rs11257655-
containing enhancer and a nearby control region with 
a T2D-associated variant (rs33932777) that lacked 
active chromatin marks in human islets. Cas9 only: 
n=6 (two independent experiments with triplicates). 
Deletions: n=8 (two single guide RNA pairs in two 
independent experiments with biological duplicates). 
Bars are means±SEM, normalised by TBP and expressed 
relative to mean levels of the Cas9 only controls. 
Statistical significance: two-tailed Student’s t-test. SNP, 
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FEATURE
in overexpression of  CAMK1D and OPTN, whereas CRISPR-mediated 
inhibition led to an opposite effect. 
At the ZBED3 T2D locus, we observed a remarkable connectivity between 
the T2D enhancer and multiple genes in the locus (Figure 3a), which was 
corroborated by the CRISPR perturbation experiments in EndoC-bH3 
cells (Figure 3b). Altogether, our experimental validations demonstrated that 
the detected chromatin enhancer–promoter interactions reflect functional 
chromatin interactions in human pancreatic islets.
This study has revealed 3D chromatin architecture analysis coupled with 
genome editing as a powerful framework for interpretation of  T2D genetic 
association signals (Figure 4). Furthermore, the results shed light into 
unexpected regulatory links that may be affected by T2D susceptibility 
variants, bringing to our attention new potential players in T2D aetiology. 
Future functional investigation of  these new T2D genes should illuminate 
their contribution to T2D risk processes.
INÊS CEBOLA
Department of Metabolism, Digestion and Reproduction, Imperial 
College London
of  human pancreatic islets at key loci, including those implicated in T2D 
genetic risk. 
With these reassuring results, we set out to validate the in silico predictions at 
ten specific islet enhancers that harbour T2D risk variants, by performing 
epigenomic modulation of  the target enhancers and/or by deleting 
them (Figure 1). Epigenomic modulation was achieved by targeting T2D 
enhancers with a catalytically inactive Cas9 (dCas9) tethered with specific 
effector domains (VP64-P65-HSF1 for CRISPR activation and KRAB 
for CRISPR inhibition). In comparison, deletion of  islet enhancers was 
achieved by co-expressing Cas9 with two single guide RNAs flanking the 
target enhancers.
One of  the investigated T2D loci was CDC123/CAMK1D, where a single 
risk variant resides in an islet enhancer with classic enhancer features (e.g. 
high chromatin accessibility and enrichment for Mediator and H3K27ac). 
Previously, human islet eQTL studies had prioritised CAMK1D as the target 
of  this enhancer variant.10 Nevertheless, our analysis by promoter capture 
Hi-C also enabled detection of  a very long range interaction with a gene 
that has not been previously implicated in diabetes, OPTN, located >800kb 
from the risk variant (Figure 2a). Deletion of  this T2D enhancer in EndoC-
bH3 cells led to marked downregulation of  both CAMK1D and OPTN, but 
not of  the nearest gene, CDC123 (Figure 2b). Further supporting our in silico 
assignments, CRISPR-mediated activation of  this T2D enhancer resulted 
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Figure 3. The ZBED3 T2D risk locus harbours an islet enhancer with 
a T2D SNP (single nucleotide polymorphism) with multiple target 
genes. (a) The T2D risk variant rs7732130 maps to a strong islet 
enhancer (yellow line and zoomed inset) that is assigned by human 
islet promoter capture Hi-C analysis to S100Z, ZBED3, ZBED3-AS1, 
snoRA47, PDE8B and WDR41. (b) Analysis of transcripts encoded in 
the locus after CRISPR activation of the rs7732130-enhancer in EndoC-
βH3 cells. Data are presented as means±SEM of three single guide 
RNAs (sgRNAs) tested in three independent experiments. Control 
sgRNAs: sgRNAs against regions not present in the human genome. 
Enhancer sgRNAs: sgRNAs designed against the summit of ATAC-seq 
signal (accessible chromatin) in the rs7732130 enhancer. Statistical 
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Figure 4. Overview of a workflow to prioritise non-coding variants 
and target gene investigation in T2D. Enhancer LOF: enhancer loss 
of function can be achieved by either indels at the core region 
(transcription factor (TF)-binding sites), full deletion or CRISPR-
mediated inhibition (CRISPRi). Enhancer GOF: CRISPR-mediated 
activation. EMSA, electrophoretic mobility shift assay; GSIS, glucose-
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ENDOCRINOLOGY: 
GETTING BACK TO BETTER
WRITTEN BY STEVE BALL
What issues do we face in resetting, restoring and 
rebuilding clinical services in the COVID-19 era?
On 30 January 2020 (a date that now seems an age ago), the UK’s  
NHS declared a level 4 critical incident in response to the emerging global  
COVID-19 pandemic. On 17 March, the NHS Chief  Executive  
Sir Simon Stevens and Chief  Operating Officer Amanda Pritchard wrote  
to NHS Trust Chief  Executives, instructing them to enact steps to  
maximise critical care capacity, prepare for the anticipated increase in 
hospital admissions and increase staff availability to support patient-facing 
roles. The instructions included a number of  operational elements:
• the postponement of  non-urgent elective surgery and other clinical 
activity
• accessing capacity in the independent sector
• support for remote working for staff at increased risk
• support for remote consultations and provision of  advice and guidance 
for outpatient and primary care
• support for clinicians to work beyond their usual boundaries and 
specialties
• a move to block contract payments ‘on account’ with suspension of  
volume-based ‘payment by result’ tariffs and the underlying financial 
architecture and processes.
The pace and scale of  the NHS response to the COVID-19 challenge was 
remarkable: testimony to the structures and processes of  the organisation, 
and to the skills and attributes of  those working within it. To many, it 
showed what could be achieved given the right conditions for change. 
We now face a different challenge: how to reset, restore and rebuild clinical 
services paused over the last 6 months. Do we return to what we had, or is 
there an opportunity to achieve something better?
THE ‘NEW NORMAL’ IN CLINICAL ENDOCRINOLOGY
In keeping with many other specialist clinical services, endocrinology in the 
UK has evolved around local and regional requirements through processes 
that have been partly strategic, partly organic. 
Some services are based in specialist centres, others within smaller hospitals 
that balance a range of  generalist and specialist services. Some regions have 
well-established and functional clinical networks, while in others services 
remain in silos.
Nationally, we see variation in pathways, performance, matching of  
demand and training outcomes: variation we have looked to address over 
time with a range of  success.
As in any large, complex system, effecting change within the NHS can be a 
slow process of  small, iterative steps. We are now presented with a bigger, 
strategic opportunity and we have an ally in change: the NHS leadership.
In a letter to NHS Chief  Executives on 29 April 2020, Sir Simon Stevens 
highlighted the opportunities to ‘lock in’ beneficial changes brought about 
during the COVID-19 response. A number of  themes covering ‘lessons 
learned’ were emphasised as being key going forward:
• flexibility
• enhanced local system working
• clinical leadership
• remote working
• rapid scaling of  new technology-enabled service delivery.
As we restore endocrinology services to the ‘new normal’ within this 
broader context, we have a window of  opportunity to embed change at 
pace and scale, such that we go back to something better. What should be 
the vision for that change?
CHANGE IN HEALTH SERVICE DELIVERY:  
THE BROAD VIEW
A number of  national groups have set out broad principles for resetting 
healthcare delivery as we emerge from the COVID-19 peak. There is 
significant common ground.
The Royal College of  Physicians has set out nine priorities in resetting and 
relaunching services. A key principle is building in long term improvements, 
with specific reference to reducing health inequalities and improving access:
• supporting integration: redesign through co-production with primary 
care, social care and patients
• increasing the workforce
• encouraging protected time for quality improvement, service redesign 
and research
• supporting education development
• securing a new deal for international workers
• enhancing person-centred care
• enabling access and involvement in research for all
• making social care sustainable
• harnessing the potential of  digital health.
The Health Foundation too has emphasised four key principles 
underpinning service restoration and reform:
• understanding and addressing the full extent of  unmet need
• reassuring the public about using services
• looking after and growing the workforce
• improving, not just recovering, services.
ENDOCRINOLOGY
The Specialist Endocrinology CRG and Society for Endocrinology have 
been working on a range of  initiatives.
A Specialist Endocrinology CRG consultation exercise on the future of  
clinical services reported in May 2020. The exercise identified strategic 
principles and specific operational elements capturing positive learning 
from the COVID-19 response that we recommended should be ‘locked 
into’ the reset and rebuild.
1. Over-arching principles:
• enhanced support for remote consultations
• wider engagement with primary and community care
• co-design of  care pathways with primary and community care
• enhancing visibility of  local clinical networks
• improving access to endocrinology MDTs.
2. Improving delivery of  specialist care:
• clearer recognition of  specialist centres.
3. Enhancing efficiency of  outpatient services:
• providing advice and guidance as an alternative to referral for 
outpatient review
• assessment and triage of  referral as standard practice in managing 
referrals
• development of  ‘confer before refer’ systems with primary care
• supporting ‘direct to test’ pathways.
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to primary care as we ‘locked down’ and reduced onward referral. While 
referrals have started to increase again, there is limited ability to ‘bounce 
back’ within the system.
The public remain wary; there is fatigue within a depleted clinical 
workforce – many of  whom were redeployed to other roles; and making 
hospitals safe for both patients and staff has reduced capacity for traditional 
ways of  working. In the short term, we risk a logjam as new incoming work 
meets that which was postponed from March–June, at a time when capacity 
is still limited. We cannot simply stop and reconfigure: the logjam will 
simply get bigger.
New ways of  working with technology are both refreshing and challenging. 
‘Remote by default’ will be the standard for outpatient consultations going 
forward, as we aim to deliver 80% of  appointments non-face-to-face. 
While there are positives to this approach, there are some uncertainties. 
Subsequent face-to-face consultations may be required for a proportion of  
patients seen remotely and, although consultations may require less physical 
infrastructure, access to testing and laboratory data can be limiting. Those 
services with a functional electronic patient record (EPR) will be more 
adaptable than others. Institutions wishing to engage in EPR platforms 
now will find themselves approaching a large financial investment at a 
time of  significant constraint. Maturity and capacity of  the NHS digital 
infrastructure may limit the pace and scale at which we can engage and 
respond.
As well as clinicians, healthcare commissioners and managers have 
an important role to play in resetting and restoring services. Financial 
structures and accounting processes may need modification to reflect 
changes in mode of  consultation and outcomes. Activity constraints 
(payment by result) versus block contracts need key reconsideration 
following service restarts. The real challenge may be for commissioners 
and managers to support clinical teams in doing the right thing: responsive 
funding packages being co-designed to support clinical innovation.
IN CONCLUSION
A pragmatic, balanced approach is needed to what lies ahead. While 
there are some ‘low hanging fruit’, it is crucial to establish the vision and 
principles behind the need for change, while building in the processes that 
will enable further progress over time. We need to ensure those processes 
are dynamic and agile, as we still face some uncertainty over when and how 
our clinical services will be asked to respond again. There is much to do. 
Get involved.
STEVE BALL
Society for Endocrinology Representative,  
Specialised Endocrinology CRG 
4. Improving access:
• developing and supporting patient group education via video 
technology
• development and implementation of  patient-initiated follow-up.
5. Training in endocrinology:
• further development of  allied health professional and clinical nurse 
specialist roles
• development and support of  e-learning platforms.
To further inform and guide adaptation in service delivery, the Society 
for Endocrinology is supporting a working group exploring the future of  
endocrinology. This will include representation from patient groups and 
the Association of  British Clinical Diabetologists, who have recently gone 
though a similar process to review services in diabetes. We look forward 
to seeing the output in the near future. Alignment, inclusion and a co-
operative approach across the system will be important determinants of  
success.
OBSTACLES AND CHALLENGES
While there is genuine excitement about the opportunities, it’s important 
we recognise the scale of  the challenge ahead. Reset and restore will not be 
straightforward. 
After the usual drop in referrals from primary to secondary care over the 
Christmas–New Year period in 2019/2020, weekly referrals peaked at 
385,503 in the week beginning 20 January 2020. There was a subsequent 
sharp fall. By mid April 2020, routine referrals had decreased by 90% 
overall. Urgent and ‘2-week’ pathway referrals fell by 78 and 67% 
respectively. This shift reflected both decreased presentation of  patients 
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STAY INFORMED ON MANAGING ENDOCRINE CONDITIONS 
DURING THE COVID-19 PANDEMIC
Read and contribute to our resource collection for your information and to share with your colleagues. 
Visit www.endocrinology.org/covid19.
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SOCIETY NEWS
2020 Awardees:  
LEADERSHIP & DEVELOPMENT  
AWARDS PROGRAMME
The Society’s ambitious Leadership & Development Awards Programme recognises and nurtures 
emerging talent, to enable our Awardees to become the future leaders of endocrinology. The scheme 
was pioneered by our former President, Graham Williams.
Join us in congratulating our 2020 Awardees, who will receive a wide range of benefits, providing 
opportunities for them to develop their careers and professional profiles. 
Watch out for updates on their progress over the next 3 years.
CLINICAL ACADEMICS
ALEXANDER COMNINOS  
Imperial College London
Alex’s research focuses on reproductive 
endocrinology, and is funded by fellowships, 
lectureships and grants from the Wellcome 
Trust, NIHR and MRC. He has received a 
number of  prestigious prizes, including the 
Reproductive Science Prize (Endocrine Society), 
and the Society for Endocrinology’s Early Career and Clinical 
Endocrinology Trust Prizes. Alex currently sits on the Society’s 
Science Committee.
JULIA PRAGUE  
Royal Devon and Exeter NHS Foundation 
Trust and University of Exeter
Julia qualified in 2008 from King’s College 
London School of  Medicine and Dentistry 
at Guy’s, King’s College and St Thomas’ 
Hospitals, with a double distinction and first class 
honours. During her PhD at Imperial College, she 
completed the first study in humans of  a neurokinin 3 receptor 
antagonist for menopausal flushes, published in The Lancet. She 
was awarded the North American Menopause Society New 
Investigator Award in 2017 and the Society’s Early Career Prize 
in 2018.
PETER TAYLOR Cardiff University and the 
University Hospital of Wales
Peter completed his PhD in thyroid 
epidemiology, and his research focuses on the 
effects of  common variation in thyroid status, 
thyroid hormone prescribing and thyroid 
screening in pregnancy. He has had considerable 
involvement in trials relating to the thyroid in 
pregnancy and thyroid eye disease. As well as receiving awards 
at both national and international conferences for his work, 
Peter has over 50 publications related to the thyroid field.
Learn more about the Society’s 
Leadership & Development Awards 





CLAIRE FLETCHER Imperial College London
Awarded a PhD in the molecular biology of  prostate cancer 
in 2013, Claire was granted a Young Investigator Award 
from the Prostate Cancer Foundation (USA) in 2016 and an 
Imperial College/AstraZeneca Research Fellowship in 2018. 
She is currently establishing an independent research team 
within the Department of  Surgery and Cancer at Imperial, to 
investigate functions of  non-coding RNAs in hormone-dependent 
cancers and drug resistance, the role of  obesity and peri-prostatic adipocytes in 
promoting lethal prostate cancer and post-transcriptional RNA modifications in 
modulating therapy responses.
TIJANA MITIC University of Edinburgh
Tijana obtained her PhD from the University of  Edinburgh in 
2010, where she completed a short postdoctoral placement. 
She then moved to a further successful postdoc at the Bristol 
Heart Institute (2011–2014) before taking a break from 
academia. In 2016, she was awarded a highly competitive 
part-time fellowship from the British Heart Foundation to restart 
her academic research. In 2019, she received a Fellowship of  the 
Higher Education Academy. She now leads a research team investigating the 
epigenetic changes in hypoxia and during vascular injury.
CLINICIANS IN PRACTICE
SAFWAAN ADAM  
The Christie Hospital, Manchester
Following graduation from the University of  Cape Town, 
Safwaan undertook early postgraduate training in South 
Africa and New Zealand, before his specialist endocrinology 
training in the North West of  England. He took time out 
of  clinical training to pursue a PhD examining the metabolic 
and cardiovascular complications of  obesity at the University 
of  Manchester. Safwaan’s research has led to a number of  presentations, 
publications and prizes. He has a particular interest in the use of  ‘real world’ 
data analytics to inform clinical practice.
JUSTYNA WITCZAK  
University Hospital of Wales, Cardiff
Justyna completed her MD at Cardiff University on the 
characterisation of  circulating extracellular vesicles in human 
obesity. Her research was supported by the Lewis Thomas 
Gibbon Jenkins of  Briton Ferry Fellowship from the Royal 
College of  Physicians. Other research interests include thyroid 
disorders and type 2 diabetes. Justyna is a Committee Member of  
the Young Diabetologist and Endocrinologist Forum Wales.
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Develop your writing skills in science:  
JOIN THE YOU AND YOUR  
HORMONES TEAM
The Society is looking for enthusiastic  
clinicians, scientists and nurses working in 
endocrinology to be Content Editors, who 
will contribute and review articles for ‘You and 
Your Hormones’, our public-facing website 
(www.yourhormones.info).
WHY SHOULD YOU APPLY?
• You’ll gain experience in an editorial role
• You can improve your writing skills for non-specialist  
 audiences
• You’ll help public engagement with endocrinology
WHAT DOES IT INVOLVE?
• Reviewing up to one article per month
• Identifying novel topics to add to the website
• Writing new articles for the website
• Ensuring information is accurate, reliable and easy to  
 understand
• Working alongside a supportive Editorial Board member
Volunteers will serve from: 
November 2020 until 31 December 2022
You can learn more at:  
www.endocrinology.org/outreach/ 
content-editors









“Being a Content  Editor tuned my  creative writing  
and editing skills.
Shanty Shah
“I have developed a number of skills essential for a future career in 
science communication.
Elizabeth Oliver
You and Your Hormones provides reliable  
online information and learning resources  
for students and the general public on 
hormones and hormone-related conditions. 
The website is written and reviewed by  
Society experts, and the Content Editors  
will support the Editorial Board to help ensure 
the latest research and clinical practice are 
included across all areas of endocrinology.
www.yourhormones.info
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ventures, including the world’s first online submission and peer review 
project. Bernard was then President of ALPSP from 2000 to 2010. In 2007, 
at his 80th birthday party, I was very pleased to be able to present him with 
Honorary Membership of the Society for Endocrinology, which he was 
really thrilled with.
After his retirement, Bernard wrote a biography of Lord Zuckerman, 
partly in an attempt to discover what had caused him to be so antagonistic 
towards Geoffrey Harris and to hold to a view that was increasingly 
shown to be erroneous. I don’t think he ever really satisfied himself on 
that question, but I was pleased to be able to publish the book through the 
Society for Endocrinology in 2005, especially as both Bernard and Solly 
had been leading lights in the Society.
As regards his personal life, Bernard had three marriages. His first marriage 
to Heather, which produced his first two children, Susan and Iain, faltered 
because his growing academic career left them little time to share activities. 
They parted in 1969 and Bernard married Jean in 1971; his third child, 
Adam, was born in 1973. By the mid-1980s, this relationship also drifted 
apart, with Jean leaving in 1987. This left Bernard to bring up Adam, and 
the two had a very close and affectionate relationship. 
During his time at ALPSP, Bernard worked closely with Eileen Storrie. 
After her husband’s death, Bernard and Eileen kept in touch and married 
in 2005. I remember being astonished by the news, and then being 
immediately convinced it was a fantastic match – Bernard described it in 
his memoir as being ‘content … even blissful’. A happy ending, indeed, and 
well-deserved. Bernard died peacefully in his sleep at the end of July.
SUE THORN 
Former Chief Executive of the Society for Endocrinology
My abiding impression is of a man with the energy and determination to 
get things done, but a quiet man who held his own without bluster, and 
who treated everyone with respect. Bernard let people realise for themselves 
his qualities from his actions. He didn’t need to self-promote, although his 
iron backbone showed itself when someone at a publishing dinner tried to 
challenge him on a fact about ferrets, on which Bernard was probably the 
world’s leading authority.
Bernard was born in Peckham in 1927 to a close family with no academic 
background. Bernard discovered fairly early that he preferred the kinds of 
play that created or achieved something. On leaving school at 16, Bernard 
began work as a lab assistant at the Wellcome Lab on Euston Road and 
spent three hours studying at Chelsea Polytechnic every weekday, after a 
full day’s work. After his matriculation, and being made a Fellow of the 
Chemical Society, he was called up and served his National Service in the 
Royal Navy, where he specialised in the maintenance of radar kit.
Bernard was then given a grant to study physiology at University College 
London. After graduating in 1952, he was awarded an MRC grant to study 
for his PhD in Geoffrey Harris’ new Department of Neuroendocrinology 
at the University of London Institute of Psychiatry. Geoffrey Harris’ theory 
was that ‘the hypothalamus produced some chemical factor, or factors, 
that controlled the release of the hormones from the pituitary gland’. It 
was Bernard’s experimental work on this with Professor Harris that led 
to the long-running and vituperative argument between Harris and Solly 
Zuckerman, on which Harris and Bernard were eventually proved right. I 
believe Bernard’s first published paper, on this subject, was in Nature.
After gaining his PhD in only two years, Bernard continued his research 
career and wrote many journal papers and book chapters during this 
period. I’m aware that many an endocrinologist recalls with affection using 
a seminal textbook written by Bernard. During this time, he had the chance 
to spend six months in Lund, working with Dora Jacobsohn, and later spent 
a year at University of California San Francisco. 
By 1972, Bernard had been awarded a DSc and then a Chair by the 
University of London. Alongside his lab work, Bernard had been getting 
more and more interested in publishing issues. In 1974 he took over as 
Editor of Journal of Endocrinology. The previous Editor had been based 
in Bristol and so Bernard was involved in the setting up of the first 
independent offices for the Journal in Bristol. At that time the journal 
was published by Cambridge University Press and was not particularly 
successful financially. Bernard was one of the team that brought the journal 
in house and they were delighted to find that they actually made a larger 
surplus that way.
Bernard’s involvement with the processes of publishing led to the Society 
becoming an early member of ALPSP, of which he was Vice-Chairman 
(1979–1980) and Chairman (1981–1986). In 1988, Bernard took early 
retirement and the role of Secretary-General of ALPSP, which is where 
I got to know him, as we worked together on early online publishing 
Remembering 
BERNARD DONOVAN
I first met Bernard in the early 1990s when he was 
Secretary-General of the Association of Learned 
and Professional Society Publishers (ALPSP). I 
was CEO of the Society for Endocrinology and 
starting to get involved with ALPSP committee 
work. At the time I had no idea that Bernard had 
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